SARS-CoV-2 viral replication persists in the human lung for several weeks after symptom

2 onset

1

3

5

- 4 **Running title:** Persistence of SARS-CoV-2 in the human lung.
- 6 Tomasicchio M^{1,2}, Jaumdally S^{1,2}, Wilson L^{1,2}, Kotze A^{1,2}, Semple L^{1,2}, Meier S^{1,2}, Pooran A^{1,2},
- Final A^{1,2}, Pillay K⁵, Roberts R⁵, Kriel R⁵, Meldau R^{1,2}, Oelofse S^{1,2}, Mandviwala C^{1,2}, Burns
- 8 J^{1,2}, Londt R^{1,2}, Davids M^{1,2}, van der Merwe^{1,2} C, Roomaney A^{1,2}, Kühn L^{1,2}, Perumal T^{1,2},
- 9 Scott A.J^{1,2}, Hale M.J⁶, Baillie V⁷, Mahtab S⁷, Williamson C⁸, Joseph R⁸, Sigal A⁹, Joubert I¹⁰,
- 10 Piercy J¹⁰, Thomson D¹⁰, Fredericks DL¹⁰, Miller MGA¹⁰, Nunes M.C⁷, Madhi S.A⁷, Dheda
- 11 $K^{1,2,3,4}$.

12

13 Affiliations:

- ¹Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine,
- University of Cape Town and UCT Lung Institute, FCape Town, South Africa.
- ² South African MRC Centre for the Study of Antimicrobial Resistance, University of Cape
- 17 Town, Cape Town, South Africa.
- ³ Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape
- 19 Town, South Africa.
- ⁴ Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection,
- 21 London School of Hygiene & Tropical Medicine, London, UK.
- ⁵ Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape
- 23 Town, South Africa
- 24 ⁶ Division of Anatomical Pathology, Faculty of Health Sciences, University of the
- 25 Witwatersrand.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

⁷ South African Medical Research Council, Vaccines and Infectious Diseases Analytics

27 Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,

South Africa; Department of Science and Technology/National Research Foundation South

29 African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences,

30 University of the Witwatersrand, Johannesburg, South Africa.

- 31 ⁸ Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine,
- 32 University of Cape Town, Cape Town, South Africa.
- ⁹ Africa Health Research Institute, Durban, South Africa.
- 34 ¹⁰ Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, University
- of Cape Town, South Africa.

36

40

- 37 Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity, Division of
- Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, South
- 39 Africa. E-mail: keertan.dheda@uct.ac.za

ABSTRACT

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

upper respiratory tract, immunology

Rationale: In the upper respiratory tract replicating (culturable) SARS-CoV-2 is recoverable for ~ 4 to 8 days after symptom onset, however, there is paucity of data about the frequency or duration of replicating virus in the lower respiratory tract (i.e. the human lung). **Objectives:** We undertook lung tissue sampling (needle biopsy), shortly after death, in 42 mechanically ventilated decedents during the Beta and Delta waves. An independent group of 18 ambulatory patents served as a control group. Methods: Lung biopsy cores from decedents underwent viral culture, histopathological analysis, electron microscopy, transcriptomic profiling and immunohistochemistry. **Results:** 38% (16/42) of mechanically ventilated decedents had culturable virus in the lung for a median of 15 days (persisting for up to 4 weeks) after symptom onset. Lung viral culture positivity was not associated with comorbidities or steroid use. Delta but not Beta variant lung culture positivity was associated with accelerated death and secondary bacterial infection (p<0.05). Nasopharyngeal culture was negative in 23.1% (6/26) of decedents despite lung culture positivity. This, hitherto, undescribed bio-phenotype of lung-specific persisting viral replication was associated with an enhanced transcriptomic pulmonary pro-inflammatory response but with concurrent viral culture positivity. **Conclusions:** Concurrent, rather than sequential active viral replication continues to drive a heightened pro-inflammatory response in the human lung beyond the second week of illness and was associated with variant-specific increased mortality and morbidity. These findings have potential implications for the design of interventional strategies and clinical management of patients with severe COVID-19 disease. 243 words **Keywords:** COVID-19, SARS-CoV-2, virus replication, mechanically ventilated patients,

At a Glance Commentary

Scientific Knowledge on the Subject:

Investigations to understand SARS-CoV-2 viral shedding (determined by PCR or antigen testing) have extensively focused on samples from the upper respiratory tract. The widely accepted view is that acute severe SARS-CoV-2 infection is characterised by a viral replicative phase in the first week of symptomatic illness followed by a pro-inflammatory immunopathologic phase peaking in the second and third weeks of illness. However, it remains unclear whether detection of SARS-CoV-2 beyond 2 weeks after symptom onset in published studies represent active replication competent virus because it may represent residual genomic or antigenic material in the tissue.

What This Study Adds to the Field:

We have identified a, hitherto, undescribed bio-phenotype of acute severe COVID-19 characterised by persisting viral replication in the lung for up to 4 weeks after symptom onset. ~40% of acute severe COVID-19 intensive care unit (ICU) decedents (n=42) had nasopharyngeal swab culture positivity at ~2 weeks post-symptom onset versus only ~5% in a group of ambulatory control patients (n=18). There was compartment-specific (nasopharynx versus lung) discordance. The phenotype of lung-specific persisting viral replication was associated with variant-specific accelerated death, an exaggerated inflammatory response, and attenuated T-cell immunity in the lung (based on histopathological and transcriptomic studies). This challenges the traditional view that viral replication occurs during the first 5 to 10 days of illness, which is followed by an effector or hyperinflammatory phase. This is the first study, to our knowledge, to systematically culture virus from the human lung and map out its related clinical determinants, and which describes the human lung transcriptomic profile of culture-positive versus culture-negative patients with severe COVID-19 disease.

Introduction.

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Coronavirus disease-19 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been the foremost killer globally over the last 3 years. Case fatality risk in hospitalised patients, and particularly in mechanically ventilated patients, during the Beta and Delta waves was particularly high [~50%-70%; (1)]. Even with the Omicronrelated variants, case fatality risk remains significant in the elderly and immunocompromised persons, and in several countries including the UK, Italy, France, Brazil, and prominently in China where there is now an ongoing epidemic of severe COVID-19 disease (2-10). Better therapeutic interventions are needed. However, despite considerable research, the pathogenesis of severe COVID-19, relative to viral kinetics, remains incompletely understood. SARS-CoV-2 detection (ascertained through PCR positivity or antigen detection) can persist for several weeks from symptom onset (11). Post-mortem studies have shown persistence of SARS-CoV-2 in tissues detected by PCR and immunohistochemistry for up to several weeks after symptom onset (12, 13). However, detection of SARS-CoV-2 in these studies may not represent replication competent virus (detectable only by viral culture) but residual genomic or antigenic material in the tissues. Shedding of replicating virus confirmed through serial viral culture (i.e. in vitro replication in human cell lines) from the upper respiratory tract (URT) has been shown to persist for only ~2 to 8 days after symptom onset (11, 14-23). These findings have been confirmed in human lung challenge studies with viable pathogen where virus was cultured from the URT until a median of 4 days (and a maximum of 10 days) from symptom onset (24). However, hardly anything is known about the compartment-specific duration of actively replicating virus in the lower respiratory tract (LRT), particularly in acute severely ill hospitalised patients undergoing mechanical ventilation. We hypothesised that there is

compartment-specific uncoupling of viral replication in severe COVID-19 i.e. replicating virus

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

can persist in the LRT beyond 10 days from symptoms onset, independent of its persistence in the URT, and this persistence may be associated with an altered pulmonary immunity. Methods. Patients. The decedents (n=42) were recruited from Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa (n=18; Beta group) and Groote Schuur Hospital, Cape Town, South Africa (n=24; Delta group). Figure 1A outlines an overview of the study plan. Ambulatory controls (n=18) were recruited at diagnosis (baseline; ~5 days from symptom onset), 7 days and 14 days post diagnosis. Minimally invasive tissue samples (MITS) and nasopharyngeal swabs from decedents (n=42) in the Beta and Delta waves (Figure 1B) were taken immediately after death. In addition, heart, liver, kidney, and adipose tissue samples were also taken from the Delta variant decedent cohort only. Ethical approval was obtained from the Human Research Ethics Committee (HREC) of the University of Cape Town (HREC approval number 866/2020) and University of Witwatersrand (HREC approval number M200313). Biosafety approvals were obtained from the Faculty Biosafety Committee of the University of Cape Town (IBC008-2021). Viral culture. To establish the *in vitro* viral culture model, a SARS-CoV-2 viral stock was used to infect the human lung carcinoma cell line, H1299 ACE2, in a BSL3 laboratory and infection was confirmed by light microscopy (as assessed by cytopathic effects of the virus on the cell line) and confocal microscopy (Figure S1A and B). Serial dilutions of the viral stock were used to establish the limit of detection of the PCR assay at 1×10^1 copies/ml (Figure S1C). Viral culture was performed on the nasopharyngeal swab and lung biopsy samples as indicated in the study

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

overview (Figure 1) and detailed in the online supplement. Viral culture result reproducibility was good (see online supplement). Multiplex PCR to detect secondary bacterial infections. The lung biopsy cores, stored in universal transport medium, were briefly homogenised and 200µl of the supernatant was applied to the BioFire FilmArray Pneumonia panel (Bioméieux, South Africa). The panel was run using protocol BAL v3.3 according to the manufacturer's instructions, thus generating RT-PCR readouts for 33 bacterial and viral pathogens. Bronchopneumonia was defined as histological evidence of a neutrophilic alveolar infiltration together with the detection of bacterial genomic material in the biopsy cores. Immunohistochemistry. Immunohistochemical staining was performed using the Roche Ventana Automated platform (Ventana XT autostainer) as indicated by the manufacturer. Tissue sections were prepared, stained, and viewed using standard techniques (25). Antibodies included anti-CD3 (2GV6), and anti-CD8 (SP57) (Roche USA). Haematoxylin & eosin (H&E) staining and transmission electron microscopy (TEM). H&E staining and TEM were performed according to standard procedures (25). H&E-stained slides were viewed using an Olympus BX43 microscope. TEM tissue sections were viewed using a Carl Zeiss EM109 microscope. SARS-CoV-2 whole genome sequencing. Total SARS-CoV-2 RNA was extracted from lung biopsy samples and whole genome sequencing was performed. The generated reads were analysed with the Exatype

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

(https://exatype.com) software to identify minor and major variants. The assembled consensus sequences were analysed using Nextclade Web (https://clades.nextstrain.org) for further quality control and clade assignment. RNAseq. Total RNA was extracted from lung biopsy samples from the Delta group, sequenced and mapped consecutively to the human and COVID reference genomes using the Spliced Transcripts Alignment to a Reference (STAR) software [version 2.7.7a, (26)]. A differential expression (DE) analysis was performed on the generated raw read count file with the edgeR (Version 3.38.4) R package (27). The DE results were ranked by fold change and the gseGO function, from the clusterProfiler R clusterProfiler [Version 4.0, (28)] R package was used to perform a gene set enrichment analysis (GSEA) for the Gene Ontology Biological Process pathways. Pathways with an FDR < 0.05 were considered significant. Confocal microscopy. The H1299 ACE2 cells were plated, infected with SARS-CoV-2 and allowed to adhere to coverslips slides overnight at 37°C. The next day the cells were stained with or without anti-SARS-CoV-2 S1 spike protein (ThermoFisher, USA) and the slides were mounted in Mowiol (Calbiochem, USA) containing n-propyl gallate (Sigma-Aldrich, Germany) as an anti-fading agent. Confocal microscopy was performed with a Zeiss Axiovert 200M LSM510 Meta NLO Confocal Microscope. Sample size calculation and statistical analysis. We hypothesised that we would detect lung culture positivity at 14 days post-symptom onset in ~33% of decedents. A sample size of ~40 participants would allow us to ascertain that level

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

of positivity with a 15% margin of error using 95% confidence and 80% power (OpenEpi, Version 3, opensource calculator). The Fisher Exact test was employed for categorical variables and for continuous variables, Mann-Whitney test was used for non-parametrically distributed data between the culturenegative and culture-positive groups (Stata version 17 or GraphPad, Version 9.4.1). A p-value of < 0.05 was considered significant for all statistical analyses. The multivariable analysis was performed in R by fitting a binomial Generalized Linear Model (GLM) to assess the association between steroid use and the presence of secondary bacterial infection on culture status. The tidymodels (version, 1.0.0) R package was used to perform predictive modelling using the glm binomial classification algorithm. To account for the small sample size, 1000 bootstraps were performed for each analysis using the "bootstraps" function (non-parametric) from the rsample package (version 1.2.0). **Results** Demographics and clinical characteristics of the decedents. The demographics of patients enrolled in the study are shown in Table S1. The median age of the patients was 53 years with 48% being males (20/42). 40.5% (17/42) had a secondary bacterial infection and 11% (4/38) had bacterial bronchopneumonia (microbiologically and histopathological confirmed). The median time from onset of symptoms to death, ICU admission to death and high flow oxygen admission to death was 17 (IQR; 9-22), 5 (2-12) and 11 (6-15) days, respectively.

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

a factor of the limited sample size; Table S5).

SARS-CoV-2 replicating persistence in the human lung of mechanically ventilated decedents. We first ascertained the frequency and duration of replicating virus in lung tissue (which to our knowledge has not been previously undertaken). Culturable virus in the lung was present in 38.1% (16/42; Figure 2A) of mechanically ventilated ICU decedents, at a median of 15 days (and up ~4 weeks; Figure S2) from symptom onset to sampling/death (Figure 3A). As expected, 56% (10/18) of a prospectively recruited control group of ambulatory patients had culturable virus, using nasopharyngeal swab samples, at day 5 from symptom onset (Figure 2B). In the same group of patients after 12- and 19- days after symptom onset, only 5.5% (1/18) and 0% (0/18), respectively, had culturable virus from their nasopharyngeal swab (Figure 2B). By contrast, 38% of nasopharyngeal swabs from the mechanically ventilated ICU descendants had culturable virus (Figure 2B), at a median of 13 days from symptom onset to sampling/death (Figure S3B). Additionally, SARS-CoV-2 could be detected by PCR in multiple organs in lung culture-positive decedents in the Delta cohort (biopsies other than the lung was not performed in the Beta cohort) suggesting widespread multi-organ viral dissemination (Figure 2C). SARS-CoV-2 was also detected in adipose tissue of culture-positive decedents (hitherto undescribed). We did not culture virus from the organs of the decedents other than the lung. Thus, viral genetic material was only detectable by PCR in the lung culture-positive patients in the other organs. This probably indicates that the virus disseminated systemically in these patients, who had chronic replicative disease in the lung and not in the other organs. We therefore only presented the PCR results from the other organs for the lung-culture positive patient samples in Figure 2C. Clinical characteristics, such as, age and comorbidities were similar in the lung culturepositive versus culture-negative groups (Table S1). We found no association between viral genetic variant and the phenotype of replicating viral persistence (although this might have been

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Time to death in the Delta and Beta groups and predictors of lung culture positivity. Next, we evaluated variant-specific relationships to clinical outcomes. Mechanically ventilated patients who were SARS-CoV-2 lung culture-positive in the Delta, but not the Beta group, had a higher proportion of accelerated death (i.e. shorter duration from symptom onset to death; Figure 3C versus 3B; p=0.004), and a higher proportion of lung-specific secondary bacterial infection (Figure 3F versus 3E; p=0.032) compared to culture-negative decedents. Similarly, to the lung culture data, the nasopharyngeal swab culture-positive Delta, but not the Beta group, had a higher proportion of accelerated death (Figure S3D versus S3C; p=0.026). The bacterial species identified from the lung biopsies of both the Beta and Delta groups included Streptococcus, Staphylococcus, Haemophilus, Acinetobacter, Proteus spp, Escherichia, Klebsiella, Enterobacter and Serratia (Table S4). Overall, both groups were infected with one or more bacteria that were sensitive or resistant to β-lactams and/or carbapenems (Table S4). Key clinical and demographic characteristics such as differences in co-morbidities (age, obesity, diabetes, HIV positivity etc; Table S1) associated as drivers of severe COVID-19 disease and poor prognosis, could not explain these observations, despite the lower population-level vaccination and pre-existing COVID-19 exposure rates in the Beta cohort. Steroid usage (proportion) was similar in the culture-positive and culture-negative groups (Table S1; though the duration of steroid usage was significantly higher in the culture negative group), and there was no significant (p>0.05) association between steroid use and lung culture positivity or the presence of secondary bacterial infection in a multivariable analysis. If anything, there was a trend (p=0.06) to greater steroid exposure in the lung culture negative group (in the multivariable analysis) arguing against its role in driving viral replication.

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

outlined above (Figure 4C and 4D; p=0.013).

Next, we interrogated whether nasopharyngeal PCR characteristics (Ct value), either at admission or close to death, could identify the phenotype of lung replicating viral persistence. However, nasopharyngeal Ct neither at admission, nor at the time of death was associated with lung culture positivity (Figure 3G). This suggests that the kinetics of viral replication was different in the upper and the lower respiratory tract. Lung immunity and histology of the culture-negative versus culture-positive groups. We then ascertained whether the phenotype of replicating viral persistence was associated with attenuated or modulated lung immunity in the Delta decedents (transcriptomic and flow cytometric studies were only carried out in Cape Town, i.e the Delta decedents, due to locationspecific availability of assays and limited Beta group biopsy cores that had been used for unrelated studies). Immunohistochemical staining indicated that there was significantly less infiltration of CD3+ T-cells, specifically CD8+ T-cells in the alveoli and interstitium of the SARS-CoV-2 culture-positive compared with the culture-negative individuals in the Delta decedents (Figure 4A and B). The typical histological features of severe COVID-19 (e.g. diffuse alveolar damage and microvascular thrombosis) were similar in the SARS-CoV-2 culture-positive and the culturenegative phenotype suggesting that these events occurred in the early rather than the persistent viral replication phase (Figure 4C, D and S4; Table S2, S3). Interestingly, we observed that some features of leukocyte hyperactivation (i.e., hemophagocytic syndrome) were more common in the SARS-CoV-2 culture-negative versus the culture-positive group, potentially in keeping with an aberrant immune response characterised by a lack of immune regulation, as

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

The transcriptional analysis of post-mortem lung tissue after adjustment for multiple testing, identified a total of 11 up- and 4 down-regulated genes in the culture-positive versus culturenegative groups (FDR<0.05; specific genes discussed further in the online supplement; Figure S6). To ensure that the transcriptional signal was uniform, lung biopsy cores from each decedent were placed in 1 tube containing RNAlater to ensure that enough genetic material was obtained. The lung-culture-positive group expressed higher levels of carbonic anhydrase 12 (CA12) than the lung culture-negative group (Figure S6 and Table S6). This protein induces a phenotype similar to high-altitude pulmonary oedema with a decreased ratio of arterial oxygen, partial pressure to fractional inspired oxygen, and a reduction of the carbon dioxide levels (29). This was associated with increased tachypnoea and fibrinogen levels/fibrin formation and the presence of hypoxia leading to acute respiratory distress syndrome [ARDS; (29)]. Another gene that was highly overexpressed in the culture-positive cohort was CD177, a glycosylphosphatidylinositol (GPI)-anchored protein expressed by neutrophils. CD177 plays a key role in neutrophil activation, transmigration and adhesion to the endothelium and is associated with the severity of COVID-19 disease (Figure 6, S6 and Table S6) (30). Fu et al (31) reported a high neutrophil to lymphocyte ratio in the alveolar spaces of the lung from deceased patients with COVID-19. Elevated levels of CD177 were recently identified by transcriptomics in the peripheral blood (32) and by proteomics in bronchoalveolar lavage cells (33) of COVID-19 patients with mild and severe disease, which supports our data of an upregulation of CD177 in the lung culture-positive decedents. Syndecan binding protein 2 was significantly upregulated in the culture-positive versus the culture-negative group (Figure S6 and Table S6). The protein is a family member of the syndecans (SDC) which are transmembrane proteoglycans that facilitate the cellular entry of SARS-CoV-2 (34). Endothelial cells express SDC2 and during virus internalization and

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

syndecans colocalize with ACE2, suggesting a jointly shared internalization pathway. Hudak et al (34) reported that entry via SDCs enabled efficient gene transduction with SARS-CoV-2 pseudovirus which implied that SDC-mediated internalisation pathway maintained the viral particles biological activity. Viruses that target SDCs in the lung may therefore interfere with SDC-dependent signalling as inhibitors to both ACE2 and syndecan reduced the cellular entry of SARS-CoV-2, thus supporting the complex nature of internalization. The GSEA performed using the full list of differentially expressed genes ranked by fold-change, identified activated pathways that were associated with a proinflammatory response related to cytokine signalling, neutrophil and monocyte chemotaxis/recruitment, and viral entry/defence, all of which are implicated in COVID-19-related hypercytokinaemia (35) (Figure 5, 6, S5, S6, Table S6 and S7A). Significantly repressed pathways were generally associated with body homeostasis (Figure 5A and B). There was also in tandem upregulation of Th1 and Th17 signalling pathways (Table S7B) but to a substantially lesser extent than that of innate cellular and signalling pathways (IL-1, IL-6 and neutrophil-related; Table S7A). These features may be consistent with an aberrant immune response including a lack of activation of regulatory and immune-suppressive pathways. T-cell exhaustion consistent with upregulation of PD-1, CTLA-4 and LAG (Table S7C) known to be associated with severe COVID-19, was not observed. The differential expression (DE) results also revealed that a number of SARS-CoV-2 genes were significantly upregulated (FDR<0.01) in the culture-positive versus the culture-negative group including nucleocapsid phosphoprotein (log2 FC=8.4) and ORF3a (log2 FC=5.5) while the surface/spike glycoprotein encoding gene had a log2 FC of 5.3 and an FDR of 0.067 (Table S6). A visual inspection of the mapped SARS-CoV-2 reads revealed that those that mapped to the 5' end of the genes were spliced with a portion mapping to the 5' leader sequence of the genome. This suggests the reads originated from sub-genomic mRNA (sgRNA) rather than genomic RNA which is consistent with the active viral replication observed in the culture-positive group.

Finally, we evaluated whether any of the DE genes could act as biomarkers discriminating between lung culture-positive and negative-individuals. Logistic regression predictive modelling revealed that *GREM1* and *FGFBP1* were associated with a sensitivity and specificity above 90% (Figure S6). Future studies are warranted to determine if these lung-based biomarkers can predict patient culture status in blood samples.

Discussion.

The widely accepted view in severe acute COVID-19 is that resolution of the initial viral replication phase in the first week after symptom onset is followed by an effector or hyperinflammatory phase in the second and third week of illness, which is characterised by diffuse alveolar damage, thrombo-inflammation, and endotheliopathy (36). Indeed, the Infectious Disease Society of America (IDSA) recommends the use of remdesivir for only 5 days in patients with severe illness and not at all in mechanically ventilated patients (37). However, our results, based on post-mortem lung biopsies obtained using minimally invasive tissue sampling methods (MITS) shortly after death indicated that, in contradistinction to the URT where replication often ceases within ~8 days from symptom onset, in the human lung virus is culturable in ~40% of mechanically ventilated patients until death (median of 15 days and up to 4 weeks after symptom onset; see Figure 1 for the study overview). To ensure reproducibility of the lung biopsy procedure, histological analysis was performed to confirm that the tissue was derived from the lung only (to ensure that there was no contamination from other tissue or muscle, which would have been detected on histopathological analysis at the

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

least to some extent). The upregulation of muscle-associated gene pathways may have been related to virus-associated myositis or ICU-associated myopathy. The culture-positive group in the Delta cohort had accelerated death and a higher proportion of secondary bacterial infection in the lung compared to the culture-negative group. This may be explained by the Delta variant being more transmissible (38), associated with enhanced replication, higher viral load (39) and greater immune escape (40) than the Beta variant. Nasopharyngeal SARS-CoV-2 viral load (based on Ct value) neither at admission nor at death, was predictive of lung culture-positivity. SARS-CoV-2 culture-positivity in the lung of decedents was associated with attenuated pulmonary T-cell immunity and an exaggerated proinflammatory phenotype. Importantly, this was concurrent with, rather than sequential to the viral replication or viral culture-positive phase. These findings challenge the traditional paradigm of an initial viral replicative phase in the first week of severe illness sequentially followed by an effector or inflammatory phase (36). Our data suggest that in ~40% of ventilated patients, viral replication persisted until death (i.e. 3rd and 4th week of illness and a median of 15 days after symptom onset) compared to ~2 to ~8 days in the URT as outlined in several studies including a live virus human challenge study (11, 14-24). One outlier study reported culturing virus from the URT for up to 3 weeks after symptom onset (41). However, a large proportion of patients were immunocompromised, samples at diagnosis and follow-up were combined (skewing the results), a high proportion of participants were healthcare workers (re-infection may have been a confounder), and as the authors suggested a limitation was that the Vero cell line used was overtly permissive to infection compared to the human lung carcinoma cell line, H1299 ACE2, which is a biologically representative cell line (and one that we used). Another recent study showed that infectious virus production peaked in the human lung within 2 days, but this model used ex vivo agarose

infused devascularised and explanted human lung slices, which are not representative of what is occurring in freshly harvested human lung (42). The culture-based findings in the aforementioned studies must be explicitly distinguished from studies that detected residual free viral genomic RNA (but not replicating virus) embedded in the respiratory tract tissue of patients that had severe disease for an extended period of time (13, 43, 44). Indeed, SARS-CoV-2 RNAs have been detected in patient tissue many months after recovery from acute infection (45-47). It was initially suggested that sgRNA (sub-genomic RNA; small strands of reversely transcribed RNA) could be used as a proxy to infer viral replication. However, several recent studies have indicated that it has poor predictive value as a proxy for viral replication (48, 49). Indeed, Stein et al (13) detected sgRNA in multiple post-mortem organ biopsies, including the brain, several months after symptom onset. Thus, the data presented in this manuscript is the first to do so conclusively and comprehensively using viral culture from lung tissue (the gold standard to detect viral replication) beyond two weeks after symptom onset.

We demonstrated active viral replication in the lungs of acutely ill ventilated patients for up to ~4 weeks after symptom onset. This challenges the current practice of using antivirals like remdesivir for only 5 days and suggests that a longer duration of treatment may be required in critically ill patients. Furthermore, antivirals like remdesivir are not recommended for use by IDSA in mechanically ventilated patients (conditional recommendation) as they felt that such patients (often in the third week of their illness) are no longer in the viral replicative phase, and published controlled trial data showed no mortality benefit of remdesivir in such patients (37, 50). However, these studies demonstrated a group effect, and the analyses did not adjust for disease severity or the time from symptom onset to death in mechanically ventilated patients (51). Our data suggest that a significant number of patients may likely benefit from antivirals during mechanical ventilation. Indeed, several observational studies have found a survival

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

benefit using remdesivir in mechanically ventilated patients, but this requires further clarification in appropriate trials (51-53). It is also possible that the very advanced immunopathology in some patients may render antivirals redundant. In a multivariate analysis we found no association between steroid usage and lung viral culture positivity - in fact, steroid usage was lower in the viral culture-positive group (and there was a trend to an inverse relationship in the multivariable analysis, and often culture positivity persisted beyond the 10 days of steroid usage. The transcriptomic data suggested that, in a significant number of patients, the hyperinflammatory and viral replication phase occur concurrently in the 3rd and 4th week of illness, in contradistinction to the widely held view that these are sequential phases. Antiviral and selective proinflammatory responses were over-represented in the SARS-CoV-2 culturepositive compared with the culture-negative decedents, and we did not detect attenuated type 1 interferon responses at the site of disease compared with other reports (54-58). Three prior studies (one that enrolled 5 COVID-19 patients) evaluated transcriptomic lung responses in patients with severe COVID-19 versus healthy controls (54, 55, 59). These first level studies logically attempted to address the significance of transcriptomic changes specific to COVID-19 by using healthy controls or non-diseased parts of the lung from lung cancer patients. However, we specifically sought to compare culture-positive versus culture-negative groups (hitherto not undertaken) to dissect out pathways that facilitate permissiveness to ongoing viral replication. We identified two lung-based biomarkers (GREM1 and FGFBP1) that could predict culturepositivity. Although these are lung-specific biomarkers, this preliminary analysis in a limited number of samples suggests that in the future, RT-PCR of tracheal aspirates or blood (if they

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

are concordant with lung findings), could potentially serve as biomarkers to identify and direct appropriate treatment protocols to culture-positive persons but further investigation is needed. There are several limitations to our findings. Firstly, our findings are relevant to acute severe COVID-19 ARDS/pneumonia requiring mechanical ventilation and may not be applicable to milder forms of disease seen in hospitalised patients or chronic infection seen in immunocompromised patients. Second, we only studied patients with the Beta and Delta variants as these were the predominant variant at the time of the study. However, Omicron has also been associated with severe disease in several settings including the surge of severe COVID-19 unfolding in China. Third, we did not study a control group comprising severe ARDS due to other causes because our express aim was to investigate the presence and duration of viral replication in the LRT in severe COVID-19 disease. Fourth, the sample size limited our ability to make conclusions about several aspects. However, the highly resource intensive and demanding nature of the study limited our ability to recruit higher numbers of participants. Fifth, it could be suggested that there may have been sampling error and variability of the viral culture assay. However, the reproducibility of the viral culture technique using 6 samples across 2 separate runs had a low standard error, which was indicative of high reproducibility. Sixth, we did not compare the culture status of the lower respiratory tract in the ambulatory controls versus the decedents. This was due to ethical reasons and the potential risks of viral transmission to the medical and research staff during bronchoscopic procedures. Finally, the transcriptional signature and flow cytometric findings may have been affected by post-death sampling, but several detailed studies have shown (60) that most protein and RNA species are preserved and stable for several hours after death. Given that biopsies for the transcriptional studies were taken ~2 hours after death, we feel they are broadly representative of the picture at the time of death.

In summary, our data suggests that in COVID-19 disease there is considerable heterogeneity in the frequency and duration of viral replication in the upper versus the lower respiratory tract (i.e. lungs) beyond the 2nd week of illness, and that in a significant proportion of seriously ill patients, persisting viral replication occurs concurrently and may drive an exaggerated proinflammatory response (higher than in culture-negative persons), rather than sequentially as it is widely believed. These findings have potential implications for the use of antiviral therapy in seriously ill patients with COVID-19 and suggest that better biomarkers are needed to identify patient phenotypes and subsets that might benefit from concurrent anti-inflammatory and antiviral therapy.

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

Figure legends. Figure 1. Study overview including SARS-CoV-2 PCR-positive ambulatory controls (A) and mechanically ventilated decedents (B) recruited during the Beta and Delta waves. Nasopharyngeal (NP) swabs from ambulatory COVID-19 controls were obtained approximately 5 days after symptom onset (diagnosis), and then at 12- and 19-days post symptom onset. Minimally invasive tissue samples (MITS) and NP swabs were retrieved from decedents shortly after death. Figure 2. Active replicating virus was recovered from the lungs of over one third of decedents (16/42). (A) Proportion of lung biopsy samples that were culture-positive from the decedents. (B) Proportion of ambulatory patient and decedent NP swab samples that were culture-positive. (C) PCR positivity of organs of lung culture-positive decedents from the Delta cohort (organs other than the lung were not culture positive). NP= nasopharyngeal. Figure 3. The phenotype of replicating viral persistence, compared to the culture-negative participants, was associated with accelerated death and a higher frequency of bacterial bronchopneumonia in the Delta but not the Beta group. (A) The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups for both groups combined, and for the Beta (B) and Delta (C) groups alone. Proportion of samples/participants with a secondary bacterial infection in culture-negative and culturepositive decedents overall i.e. the combined groups (Beta and Delta) (**D**), Beta group only (**E**), and Delta group only (F). (G) PCR cycle threshold (Ct) value at the time of death or at admission could not discriminate or predict lung culture status. The nasopharyngeal swab PCR Ct values at admission or death were missing for some participants because they were either

diagnostically confirmed by antigen testing or the Ct value was not recorded. Due to the nature of the pandemic and the burden of the disease on the healthcare infrastructure at the time, Ct values at peak periods were not recorded. We have conducted sensitivity and imputation analyses indicating that these missing data points are redundant.

Figure 4. A higher proportion of T-cells, macrophages and pneumonocytes infiltrate into the lung of the culture-negative versus culture-positive decedents in the Delta group. (A) More CD3+ and CD8+ T-cells infiltrate into the alveoli and interstitial space of the lung culture-negative versus culture-positive group in the Delta decedents as assessed by immunohistochemistry. (B) Representative images (immunohistochemistry) at 200× magnification showing increased T-cell infiltration into the interstitial space (blue arrow) in the lung culture-negatives versus the culture-positives in the Delta cohort. The density of CD3+ or CD8+ T-cells in the alveoli or interstitial tissue were assessed and scored as medium or high. A magnitude of 10%-50% or >50% was defined as medium or high infiltration, respectively. Histopathology findings (C) and representative images (D) associated with diffuse alveolar damage and microvascular thrombosis in the Delta decedents. The black arrows indicate key histopathological features. The magnification settings were either set at 200× or 400×. The relative magnification of each light microscopy image is shown.

Figure 5. The transcriptomic analysis revealed that the culture-positive group, in comparison to the culture-negative group, had enrichment of activated pathways associated with inflammation, innate immunity, responses to cytokines, and responses to virus/ bacterial stimuli in the Delta descendants. Dot plot illustrating the significantly activated and suppressed pathways along with the gene count and ratio for each pathway (A),

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

enrichment map illustrating the significantly activated and suppressed pathways along with the gene count and ratio for each pathway (B). Figure 6. Transcriptomic analysis showing the association between the innate immune response, response to virus, response to cytokine, inflammatory pathways and genes upregulated in the culture-positive group versus the culture-negative group. The cnetplot illustrates the overlap of genes and their fold changes for selected activated pathways. Significant genes (p.adjust < 0.05) that are annotated to the pathways are highlighted in red. **Contributions** K.D, MT, S.J, A.P, A.E, M.D, M.N and S.M conceived and designed experiments. K.D, A.E, S.O, L.K, T.P, A.S, I.J, J.P, D.T, D.F, M.M, M.N and S.M arranged medical ethical approval, recruitment of study participants and collection of study material. MT, S.J, L.W, A.K, S.M, A.P, K.P, R.R, R.K, R.M, C.M, J.B, R.L, M.D, C vdM, A.R, M.H, V.B, S. M, C.W, and R.J performed the experiments. M.T, S.J, A.P and M.D set up experimental assays. A.S provided the cell line. K.D, M.T, S.J, L.W, A.K, L.S, S.M, A.P, K.P, R.R, R.L, M.H, V.B, S.M, R.J, and N.M analysed and interpreted data. K.D, M.T, L.S, and S.M wrote the manuscript with input from all listed authors. **Declaration of interests** The authors have no competing interests. **Acknowledgments** The authors would like to thank Arnold-Day C, Crowther M, Fernandes N, and Mitchell L from the Division of Critical Care, Department of Anaesthesia and Perioperative Medicine,

University of Cape Town, South Africa for identifying and referring potential patients into the study. The study was funded by the Bill & Melinda Gates Foundation (grant number INV-017282) and the South African Medical Research Council (grant number SHIP NCD 96756) with partial support from the Department of Science and Technology and National Research Foundation: South African Research Chair Initiative in Vaccine Preventable Diseases. The KD lab acknowledges funding from the SA MRC (RFA-EMU-02-2017), EDCTP (TMA-2015SF-1043, TMA-1051-TESAIII, TMA-CDF2015), UK Medical Research Council (MR/S03563X/1), NIH (CRDF-OISE-16-62105) and the Wellcome Trust (MR/S027777/1). This work was co-funded by The Wellcome Centre for Infectious Diseases Research in Africa is supported by core funding from the Wellcome Trust (230135/Z/16/Z) and the European Union's Horizon Europe Research and Innovation Actions (101046041) for genomic surveillance. The authors would like to thank the families of the deceased who gave us permission to conduct the study, which may advance our understanding of SARS-CoV-2 pathogenesis to inform future clinical management of respiratory pathogen pandemics.

References.

572

582

583

584 585

586

587

588

589

590

591 592

593 594

595

596 597

598

599

602

603

604

605

606

607

608

609

610

- 573 1. Davies MA, Morden E, Rosseau P, Arendse J, Bam JL, Boloko L, Cloete K, Cohen C, Chetty N, Dane P, Heekes A, Hsiao NY, Hunter M, Hussey H, Jacobs T, Jassat W, Kariem S, Kassanjee 574 575 R, Laenen I, Roux SL, Lessells R, Mahomed H, Maughan D, Meintjes G, Mendelson M, 576 Mnguni A, Moodley M, Murie K, Naude J, Ntusi NAB, Paleker M, Parker A, Pienaar D, Preiser 577 W, Prozesky H, Raubenheimer P, Rossouw L, Schrueder N, Smith B, Smith M, Solomon W, 578 Symons G, Taljaard J, Wasserman S, Wilkinson RJ, Wolmarans M, Wolter N, Boulle A. 579 Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by 580 Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. Int J Infect Dis 2022; 127: 63-68. 581
 - 2. Johns Hopkins University Center for Systems Science and Engineering. Accessed on: 18 December 2022. Available at: https://coronavirus.jhu.edu/map.html 2022.
 - 3. Cai J, Deng X, Yang J, Sun K, Liu H, Chen Z, Peng C, Chen X, Wu Q, Zou J, Sun R, Zheng W, Zhao Z, Lu W, Liang Y, Zhou X, Ajelli M, Yu H. Modeling transmission of SARS-CoV-2 Omicron in China. Nat Med 2022; 28: 1468-1475.
 - 4. Chen X, Yan X, Sun K, Zheng N, Sun R, Zhou J, Deng X, Zhuang T, Cai J, Zhang J, Ajelli M, Yu H. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022. Emerg Microbes Infect 2022; 11: 2800-2807.
 - 5. Colnago M, Benvenuto GA, Casaca W, Negri RG, Fernandes EG, Cuminato JA. Risk factors associated with mortality in hospitalized patients with COVID-19 during the Omicron wave in Brazil. *Bioeng* 2022; 9.
 - 6. Gautret P, Hoang VT, Jimeno MT, Lagier JC, Rossi P, Fournier PE, Colson P, Raoult D. The severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille, France, December 2021-February 2022. J Med Virol 2022; 94: 3494-3497.
 - 7. Jassat W, Mudara C, Ozougwu L, Tempia S, Blumberg L, Davies MA, Pillay Y, Carter T, Morewane R, Wolmarans M, von Gottberg A, Bhiman JN, Walaza S, Cohen C, group Da. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. Lancet Glob 2021; 9: e1216-e1225.
- 8. Maruotti A, Ciccozzi M, Jona-Lasinio G. COVID-19-induced excess mortality in Italy during the 600 601 Omicron wave. *IJID Reg* 2022; 4: 85-87.
 - 9. Maslo C MA, Laubscher A, Toubkin M, Sitharam L, Feldman C, Richards GA. COVID-19: A comparative study of severity of patients hospitalized during the first and the second wave in South Africa. MedRXiv 2021.
 - 10. Ward IL, Bermingham C, Ayoubkhani D, Gethings OJ, Pouwels KB, Yates T, Khunti K, Hippisley-Cox J, Banerjee A, Walker AS, Nafilyan V. Risk of covid-19 related deaths for SARS-CoV-2 Omicron (B.1.1.529) compared with Delta (B.1.617.2): retrospective cohort study. BMJ 2022; 378: e070695.
 - 11. Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. Infect Control Hosp Epidemiol 2021; 42: 659-668.
- 612 12. Ramos-Rincon JM, Herrera-Garcia C, Silva-Ortega S, Portilla-Tamarit J, Alenda C, Jaime-Sanchez FA. Arenas-Jimenez J, Fornes-Riera FE, Scholz A, Escribano I, Pedrero-Castillo V, Munoz-613 614 Miguelsanz C, Orts-Llinares P, Marti-Pastor A, Amo-Lozano A, Garcia-Sevila R, Ribes-615 Mengual I, Moreno-Perez O, Concepcion-Aramendia L, Merino E, Sanchez-Martinez R, Aranda I. Pathological findings associated with SARS-CoV-2 on postmortem core biopsies: 616 617 correlation with clinical presentation and disease course. Front Med 2022; 9: 874307.
- 13. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, Winkler CW, Sun J, Dickey JM, 618 Ylaya K, Ko SH, Platt AP, Burbelo PD, Quezado M, Pittaluga S, Purcell M, Munster VJ, 619 620 Belinky F, Ramos-Benitez MJ, Boritz EA, Lach IA, Herr DL, Rabin J, Saharia KK, Madathil 621 RJ, Tabatabai A, Soherwardi S, McCurdy MT, Consortium NC-A, Peterson KE, Cohen JI, de Wit E, Vannella KM, Hewitt SM, Kleiner DE, Chertow DS. SARS-CoV-2 infection and 622 623 persistence in the human body and brain at autopsy. *Nature* 2022; 612: 758-763.
- 624 14. Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, Kumar S, Tran T, Ko D, 625 Sivaruban T, Ngo C, Toi C, O'Sullivan MV, Sintchenko V, Chen SC, Maddocks S, Dwyer DE,

- 626 Kok J. Cell-based culture informs infectivity and safe de-isolation assessments in patients with 627 coronavirus disease 2019. Clinical infectious diseases: an official publication of the Infectious 628 Diseases Society of America 2021; 73: e2952-e2959.
- 15. Berengua C, Lopez M, Esteban M, Marin P, Ramos P, Cuerpo MD, Gich I, Navarro F, Miro E, 629 630 Rabella N. Viral culture and immunofluorescence for the detection of SARS-CoV-2 infectivity 631 in RT-PCR positive respiratory samples. J Clin Virol 2022; 152: 105167.
- 632 16. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A, 633 Schiffman Z, Doan K, Bastien N, Li Y, Van Caeseele PG, Poliquin G. Predicting infectious 634 severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis 2020; 635 71: 2663-2666.
- 17. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. Positive RT-PCR test results in patients recovered 636 637 from COVID-19. JAMA 2020; 323: 1502-1503.
- 638 18. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang 639 S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J 2020; 133: 1039-1043. 640

642

643

644

645

646

647 648

649 650

651

652

653

654

655

656

657

664

665 666

667

668

669

- 19. Santos Bravo M, Berengua C, Marin P, Esteban M, Rodriguez C, Del Cuerpo M, Miro E, Cuesta G, Mosquera M, Sanchez-Palomino S, Vila J, Rabella N, Marcos MA. Viral culture confirmed SARS-CoV-2 subgenomic RNA value as a good surrogate marker of infectivity. J Clin Microbiol 2022; 60: e0160921.
- 20. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M, Gopal R. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill 2020; 25.
- 21. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, van den Akker JPC, Endeman H, Gommers D, Cornelissen JJ, Hoek RAS, van der Eerden MM, Hesselink DA, Metselaar HJ, Verbon A, de Steenwinkel JEM, Aron GI, van Gorp ECM, van Boheemen S, Voermans JC, Boucher CAB, Molenkamp R, Koopmans MPG, Geurtsvankessel C, van der Eijk AA. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun 2021; 12: 267.
- 22. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581: 465-469.
- 658 23. Young BE, Ong SWX, Ng LFP, Anderson DE, Chia WN, Chia PY, Ang LW, Mak TM, Kalimuddin 659 S, Chai LYA, Pada S, Tan SY, Sun L, Parthasarathy P, Fong SW, Chan YH, Tan CW, Lee B, Rotzschke O, Ding Y, Tambyah P, Low JGH, Cui L, Barkham T, Lin RTP, Leo YS, Renia L, 660 Wang LF, Lye DC, Singapore Novel Coronavirus Outbreak Research T. Viral dynamics and 661 immune correlates of coronavirus disease 2019 (COVID-19) severity. Clin Infect Dis 2021; 73: 662 663 e2932-e2942.
 - 24. Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, Lindsell K, Hare SS, Brown J, Frise R, Smith E, Hopkins C, Noulin N, Londt B, Wilkinson T, Harden S, McShane H, Baillet M, Gilbert A, Jacobs M, Charman C, Mande P, Nguyen-Van-Tam JS, Semple MG, Read RC, Ferguson NM, Openshaw PJ, Rapeport G, Barclay WS, Catchpole AP, Chiu C. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med 2022; 28: 1031-1041.
 - 25. Suvarna SK, Layton C, Bancroft JD. Banfords theory and practice of histology techniques. Elsevier
- 672 26. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinform 2013; 29: 15-21. 673
- 27. Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG, 674 675 Bennett R, Bhai J, Billis K, Boddu S, Charkhchi M, Cummins C, Da Rin Fioretto L, Davidson 676 C, Dodiya K, El Houdaigui B, Fatima R, Gall A, Garcia Giron C, Grego T, Guijarro-Clarke C, Haggerty L, Hemrom A, Hourlier T, Izuogu OG, Juettemann T, Kaikala V, Kay M, Lavidas I, 677 Le T, Lemos D, Gonzalez Martinez J, Marugan JC, Maurel T, McMahon AC, Mohanan S, 678 679 Moore B, Muffato M, Oheh DN, Paraschas D, Parker A, Parton A, Prosovetskaia I, Sakthivel 680 MP, Salam AIA, Schmitt BM, Schuilenburg H, Sheppard D, Steed E, Szpak M, Szuba M, Taylor

- K, Thormann A, Threadgold G, Walts B, Winterbottom A, Chakiachvili M, Chaubal A, De 681 682 Silva N, Flint B, Frankish A, Hunt SE, GR II, Langridge N, Loveland JE, Martin FJ, Mudge 683 JM, Morales J, Perry E, Ruffier M, Tate J, Thybert D, Trevanion SJ, Cunningham F, Yates AD, Zerbino DR, Flicek P. Ensembl 2021. Nucleic Acids Res 2021; 49: D884-D891. 684
- 28. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X, 685 686 Yu G. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innov* 2021; 687 2: 100141.

689

690

691 692

693

694

695

696

697

698

699

700 701

702

703

704

705

706

707

708

712 713

724

- 29. Deniz S, Uysal TK, Capasso C, Supuran CT, Ozensoy Guler O. Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection? J Enzyme Inhib Med Chem 2021; 36: 1230-1235.
- 30. Levy Y, Wiedemann A, Hejblum BP, Durand M, Lefebvre C, Surenaud M, Lacabaratz C, Perreau M, Foucat E, Dechenaud M, Tisserand P, Blengio F, Hivert B, Gauthier M, Cervantes-Gonzalez M, Bachelet D, Laouenan C, Bouadma L, Timsit JF, Yazdanpanah Y, Pantaleo G, Hocini H, Thiebaut R, French Ccsg. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. iScience 2021; 24: 102711.
- 31. Fu J, Kong J, Wang W, Wu M, Yao L, Wang Z, Jin J, Wu D, Yu X. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thromb Res 2020; 192: 3-8.
- 32. Aschenbrenner AC, Mouktaroudi M, Kramer B, Oestreich M, Antonakos N, Nuesch-Germano M, Gkizeli K, Bonaguro L, Reusch N, Bassler K, Saridaki M, Knoll R, Pecht T, Kapellos TS, Doulou S, Kroger C, Herbert M, Holsten L, Horne A, Gemund ID, Rovina N, Agrawal S, Dahm K, van Uelft M, Drews A, Lenkeit L, Bruse N, Gerretsen J, Gierlich J, Becker M, Handler K, Kraut M, Theis H, Mengiste S, De Domenico E, Schulte-Schrepping J, Seep L, Raabe J, Hoffmeister C, ToVinh M, Keitel V, Rieke G, Talevi V, Skowasch D, Aziz NA, Pickkers P, van de Veerdonk FL, Netea MG, Schultze JL, Kox M, Breteler MMB, Nattermann J, Koutsoukou A, Giamarellos-Bourboulis EJ, Ulas T, German C-OI. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Genome Med 2021;
- 709 33. Zeng HL, Chen D, Yan J, Yang Q, Han QQ, Li SS, Cheng L. Proteomic characteristics of 710 bronchoalveolar lavage fluid in critical COVID-19 patients. The FEBS journal 2021; 288: 5190-711
 - 34. Hudak A, Letoha A, Szilak L, Letoha T. Contribution of Syndecans to the Cellular Entry of SARS-CoV-2. *Int J Mol Sci* 2021; 22.
- 714 35. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we 715 know so far. Front Immunol 2020; 11: 1446.
- 716 36. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. 717 Science 2022; 375: 1122-1127.
- 37. Bhimraj A MR, Shumaker AH, Baden L, Cheng VC, Edwards KM, Gallagher JC, Gandhi RT, 718 Muller WJ, Nakamura MM, O'Horo JC, Shafer RW, Shoham S, Murad MH, Mustafa RA, 719 720 Sultan S, Falck-Ytte Y. IDSA Guidelines on the Treatment and Management of Patients with 721 COVID-19. Accessed on: 18 December 2022. Available at: https://www.idsociety.org/practice-722 guideline/covid-19-guideline-treatment-and-management/#Recommendations15-17:Remdesivir. 2022. 723
 - 38. Chavda VP, Apostolopoulos V. Global impact of delta plus variant and vaccination. Expert Rev Vaccines 2022; 21: 597-600.
- 726 39. Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher 727 compared to the ancestral SARS-CoV-2 virus. J Travel Med 2021; 28.
- 728 40. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira I, Datir R, Collier DA, Albecka A, Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T, 729 730 Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O, 731 Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R, Agarwal M, Indian S-C-GC, Genotype to Phenotype Japan C, Collaboration C-NBC-, 732
- Mavousian A, Lee JH, Bassi J, Silacci-Fegni C, Saliba C, Pinto D, Irie T, Yoshida I, Hamilton 733
- 734 WL, Sato K, Bhatt S, Flaxman S, James LC, Corti D, Piccoli L, Barclay WS, Rakshit P, Agrawal

735 A, Gupta RK. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 736 2021; 599: 114-119.

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754 755

756

757

758

759

760

761 762

763

764 765

766

767

768

769

770 771

772

773

774

775

776

777 778

779

780

781

782

783 784

785


- 41. Folgueira MD, Luczkowiak J, Lasala F, Perez-Rivilla A, Delgado R. Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19. Clin Microbiol Infect 2021; 27: 886-891.
 - 42. Pechous RD, Malaviarachchi PA, Banerjee SK, Byrum SD, Alkam DH, Ghaffarieh A, Kurten RC, Kennedy JL, Xuming Z. An ex vivo human precision-cut lung slice platform provides insight into SARS2 CoV-2 pathogenesis and antiviral drug efficacy. bioRxiv 2023.
 - 43. Xu Q, Milanez-Almeida P, Martins AJ, Radtke AJ, Hoehn KB, Oguz C, Chen J, Liu C, Tang J, Grubbs G, Stein S, Ramelli S, Kabat J, Behzadpour H, Karkanitsa M, Spathies J, Kalish H, Kardava L, Kirby M, Cheung F, Preite S, Duncker PC, Kitakule MM, Romero N, Preciado D, Gitman L, Koroleva G, Smith G, Shaffer A, McBain IT, McGuire PJ, Pittaluga S, Germain RN, Apps R, Schwartz DM, Sadtler K, Moir S, Chertow DS, Kleinstein SH, Khurana S, Tsang JS, Mudd P, Schwartzberg PL, Manthiram K. Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children. Nat Immunol 2023; 24: 186-199.
- 44. Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rossler A, Kimpel J, Adolph TE, Tilg H. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterol 2022; 163: 495-506 e498.
- 45. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins M, Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. NEJM 2020; 383: 2291-2293.
- 46. Griffin I, Woodworth KR, Galang RR, Burkel VK, Neelam V, Siebman S, Barton J, Manning SE, Aveni K, Longcore ND, Harvey EM, Ngo V, Mbotha D, Chicchelly S, Lush M, Eckert V, Dzimira P, Sokale A, Valencia-Prado M, Azziz-Baumgartner E, MacNeil A, Gilboa SM, Tong VT. Recurrent SARS-CoV-2 RNA detection after COVID-19 illness onset during pregnancy. Emerg Infect Dis 2022; 28: 873-876.
- 47. Rodriguez-Grande C, Alcala L, Estevez A, Sola-Campoy PJ, Buenestado-Serrano S, Martinez-Laperche C, Manuel de la Cueva V, Alonso R, Andres-Zayas C, Adan-Jimenez J, Losada C, Rico-Luna C, Comas I, Gonzalez-Candelas F, Catalan P, Munoz P, Perez-Lago L, Garcia de Viedma D, Gregorio Maranon Microbiology IDCSG. Systematic genomic and clinical analysis of severe acute respiratory syndrome coronavirus 2 reinfections and recurrences involving the same strain. Emerg Infect Dis 2022; 28: 85-94.
- 48. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. *Nat Commun* 2020; 11: 6059.
- 49. Hwang HS, Lo CM, Murphy M, Grudda T, Gallagher N, Luo CH, Robinson ML, Mirza A, Conte M, Conte A, Zhou R, Vergara C, Brooke CB, Pekosz A, Mostafa HH, Manabe YC, Thio CL, Balagopal A. Characterizing SARS-CoV-2 transcription of subgenomic and genomic RNAs during early human infection using multiplexed droplet digital polymerase chain reaction. JInfect Dis 2023; 227: 981-992.
- 50, WHO Solidarity Trial Consortium, Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 2022; 399: 1941-1953.
- 51. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, Members A-SG. Remdesivir for the treatment of Covid-19 final report. NEJM 2020; 383: 1813-1826.
- 52. Lapadula G, Bernasconi DP, Bellani G, Soria A, Rona R, Bombino M, Avalli L, Rondelli E, 787 788 Cortinovis B, Colombo E, Valsecchi MG, Migliorino GM, Bonfanti P, Foti G, Remdesivir-Ria


perpetuity.

It is made available under a CC-BY-ND 4.0 International license .


789 Study G. Remdesivir use in patients requiring mechanical ventilation due to COVID-19. *Open Forum Infect Dis* 2020; 7: ofaa481.


- 53. Pasquini Z, Montalti R, Temperoni C, Canovari B, Mancini M, Tempesta M, Pimpini D, Zallocco N, Barchiesi F. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. *J Antimicob Chemother* 20; 75: 3359-3365.
- 54. Budhraja A, Basu A, Gheware A, Abhilash D, Rajagopala S, Pakala S, Sumit M, Ray A, Subramaniam A, Mathur P, Nambirajan A, Kumar S, Gupta R, Wig N, Trikha A, Guleria R, Sarkar C, Gupta I, Jain D. Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality. *Dis Model Mech* 2022; 15.
- 55. Melms JC, Biermann J, Huang H, Wang Y, Nair A, Tagore S, Katsyv I, Rendeiro AF, Amin AD, Schapiro D, Frangieh CJ, Luoma AM, Filliol A, Fang Y, Ravichandran H, Clausi MG, Alba GA, Rogava M, Chen SW, Ho P, Montoro DT, Kornberg AE, Han AS, Bakhoum MF, Anandasabapathy N, Suarez-Farinas M, Bakhoum SF, Bram Y, Borczuk A, Guo XV, Lefkowitch JH, Marboe C, Lagana SM, Del Portillo A, Tsai EJ, Zorn E, Markowitz GS, Schwabe RF, Schwartz RE, Elemento O, Saqi A, Hibshoosh H, Que J, Izar B. A molecular single-cell lung atlas of lethal COVID-19. *Nature* 2021; 595: 114-119.
- 56. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Mat Rev Immunol* 2020; 20: 363-374.
- 57. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, Engel JJ, Wiersinga WJ, Vlaar APJ, Shankar-Hari M, van der Poll T, Bonten M, Angus DC, van der Meer JWM, Netea MG. A guide to immunotherapy for COVID-19. *Nat Med* 2022; 28: 39-50.
- 58. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, Coppi A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Yale IT, Dela Cruz C, Farhadian SF, Schulz WL, Ma S, Grubaugh ND, Ko AI, Iwasaki A, Ring AM. Diverse functional autoantibodies in patients with COVID-19. *Nature* 2021; 595: 283-288.
- 59. Wang S, Yao X, Ma S, Ping Y, Fan Y, Sun S, He Z, Shi Y, Sun L, Xiao S, Song M, Cai J, Li J, Tang R, Zhao L, Wang C, Wang Q, Zhao L, Hu H, Liu X, Sun G, Chen L, Pan G, Chen H, Li Q, Zhang P, Xu Y, Feng H, Zhao GG, Wen T, Yang Y, Huang X, Li W, Liu Z, Wang H, Wu H, Hu B, Ren Y, Zhou Q, Qu J, Zhang W, Liu GH, Bian XW. A single-cell transcriptomic landscape of the lungs of patients with COVID-19. *Nat Cell Biol* 2021; 23: 1314-1328.
- 60. Deinhardt-Emmer S, Wittschieber D, Sanft J, Kleemann S, Elschner S, Haupt KF, Vau V, Haring C, Rodel J, Henke A, Ehrhardt C, Bauer M, Philipp M, Gassler N, Nietzsche S, Loffler B, Mall G. Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage. *Elife* 2021; 10.





^{*}The 16 decedents that were nasopharyngeal culture-positive were not the same patients that were lung culture-positive. #Immunohistochemistry, RNAseq, electron microscopy and viral culture of other organs was only performed on the Delta cohort.






Α

D

Proportion secondary bacterial infection (%)



A

Proportion of CD3+ T-cells and CD8+ T-cells infiltrating into the alveoli and interstitial space in culture-negative and culture-positive individuals in the Delta group

| medRxiv | preprint doi: https://doi.org/10.1101/2023.03.06.232868.44 Htt Gracohads ut 10.24. The copyright holder for th (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in the | | | |
|----------|--|---|------------|---------|
| preprint | Frequency of It is made available | tne autnor/funder, who has gra _nepetinity=1 1 # under a CC-BY-ND 4.0 Interna | +ve (n=7*) | p value |
| | infiltration into the | | | |
| | alveoli | | | |
| | CD3+ | | | |
| | Medium | 55% (6/11) | 0% (0/7) | 0.038 |
| | High | 0% (0/11) | 0% (0/7) | N/A |
| | CD8+ | | | |
| | Medium | 54.5%(6/11) | 0% (0/7) | 0.038 |
| | High | 0% (0/11) | 0% (0/6) | N/A |
| | | | | |

C

Key histopathological findings in the of the culturenegative and culture-positive individuals in the Delta group


| | Lung culture status | | | |
|----------------------|---------------------|--------------|---------|--|
| Lung histology | -ve (n=20◆) | +ve (n=13*) | p-value | |
| Alveolar hyaline | 16/20 (80%) | 8/13 (61.5%) | 0.425 | |
| membranes | | | | |
| Microvascular | 6/20 (30%) | 5/13 (38.5%) | 0.714 | |
| thrombosis | | | | |
| Organising hyaline | 9/12 (75%) | 6/7 (86%) | 1 | |
| membranes | | | | |
| Type II pneumocytes | 20/20 (100%) | 10/13 (77%) | 0.052 | |
| proliferation | | | | |
| Organising pneumonia | 6/20 (30%) | 4/13 (31%) | 1 | |
| Lung | 14/20 (70%) | 3/13 (23%) | 0.013 | |
| haemophagocytosis | | | | |
| | | | | |

Representative images showing CD3+ and CD8+ T-cells infiltration into the alveoli and interstitial space of the lung in culture-negative compared to culturepositive individuals in the Delta decedents

Lung culture-negative


CD3+ T-cells CD8+ T-cells 200× 200× ×

Lung culture-positive




Both culture-positive and culture-negative decedents present with histopathological findings typically associated with SARS-CoV-2 pneumonia


Alveolar hyaline membranes




В


D













Pulmonary vascular endotheliopathy



Association of the innate immune response, response to virus, response to cytokine, inflammatory pathways and genes upregulated in the culture-positive group compared to the culture-negative group



ONLINE DATA SUPPLEMENT

SARS-CoV-2 viral replication persists in the human lung for several weeks after symptom onset

Tomasicchio M^{1,2}, Jaumdally S^{1,2}, Wilson L^{1,2}, Kotze A^{1,2}, Semple L^{1,2}, Meier S^{1,2}, Pooran A^{1,2}, Esmail A^{1,2}, Pillay K⁵, Roberts R⁵, Kriel R⁵, Meldau R^{1,2}, Oelofse S^{1,2}, Mandviwala C^{1,2}, Burns J^{1,2}, Londt R^{1,2}, Davids M^{1,2}, van der Merwe^{1,2} C, Roomaney A^{1,2}, Kühn L^{1,2}, Perumal T^{1,2}, Scott A.J^{1,2}, Hale M.J⁶, Baillie V⁷, Mahtab S⁷, Williamson C⁸, Joseph R⁸, Sigal A⁹, Joubert I¹⁰, Piercy J¹⁰, Thomson D¹⁰, Fredericks DL¹⁰, Miller MGA¹⁰, Nunes M.C⁷, Madhi S.A⁷, Dheda K^{1,2,3,4}.

¹ Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.

² South African MRC Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.

³ Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

⁴ Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK.

⁵ Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape Town, South Africa

⁶ Division of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand.

⁷ South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,

South Africa; Department of Science and Technology/National Research Foundation South

African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences,

University of the Witwatersrand, Johannesburg, South Africa.

⁸ Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine,

University of Cape Town, Cape Town, South Africa.

⁹ Africa Health Research Institute, Durban, South Africa.

¹⁰ Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, University

of Cape Town, South Africa

Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity, Division of

Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, South

Africa. E-mail: keertan.dheda@uct.ac.za

Methods.

Viral culture.

The cell line was maintained in Roswell Parks Memorial medium (RPMI) containing 10% foetal bovine serum, 100 IU penicillin/streptomycin, 2 mM L-glutamine, 25 mM HEPES, 1× non-essential amino acids and 0.1 mg/mL sodium pyruvate (ThermoFisher, South Africa; Figure S1). The nasopharyngeal swabs in universal transport medium (UTM) were initially filtered through a 0.22µm filter prior to inoculation. The lung biopsy samples were placed in the well containing the cellular monolayer. The inoculated cultures were grown in a humidified 37°C incubator with 5% CO₂ and cytopathic effect (CPE) and viral replication were monitored on days 1, 3, 6 and 9 by PCR. Viral culture positivity was defined as at least a 3-fold increase in viral load over time. Viral culture reproducibility was performed by a single observer with a total of 6 different viral culture experiments. Each viral culture was performed over a 6-day period with 3 sampling time points (days 1, 3 and 6) and the experiments were all plotted over the assay timepoints to enable line fitment between the data points. A R² value of 0.94 (p=0.017) was obtained (1 being a perfect value), which indicated that the assay was highly reproducible.

Immunohistochemistry.

Sections between 3-4µm thick were placed on adhesive slides and fixed at 37°C overnight. Heat induced epitope retrieval (HIER) time was set to 60 minutes to prevent tissue wash off and possible background staining. The antibodies (anti-CD3 [2GV6], anti-CD4 [SP35], anti-CD8 [SP57] and anti-CD68 [KP-1]; Roche USA) were incubated with the tissue sections for 30 minutes. After antibody and counter staining, slides were visualised using an Olympus BX41 microscope at 40x magnification.

SARS-CoV-2 whole genome sequencing.

Total SARS-CoV-2 RNA was extracted from lung biopsy samples using the ChemagicTM 360 automated system (PerkinElmer, Inc, Waltham, MA) according to the chemagic Viral300 360 H96 drying prefilling VD200309.che protocol. Whole genome amplification and library preparation were performed using the Illumina COVIDSeq Test kit and protocol 1000000128490 v02 (Illumina, Inc., San Diego, CA), and executed on the Hamilton Next Generation StarLet (Hamilton Company). Whole genome amplification was achieved via multiplex polymerase chain reaction performed with the ARTIC V4.1 primers designed to generate 400-bp amplicons with an overlap of 70 bp that spans the 30 kb genome of SARS-CoV-2. Indexed paired-end libraries were normalized to 4 nM concentration, pooled, and denatured with 0.2 N sodium acetate. A 4pM pooled library was spiked with 1% PhiX Control v.3 adaptor-ligated library (Illumina, Inc., San Diego, CA) and sequenced using the MiSeq® Reagent Kit v2 (500 cycle) and sequenced on the MiSeq instrument (Illumina, Inc., San Diego, CA). The quality of sequencing reads was assessed using different tools including FastQC, Fastp, Fasty, Fastq screen, and Fastx toolkit. The resulting reads were analysed on Exatype (https://exatype.com/) for referenced-based genome assembly to identify minor and major variants. The assembled consensus sequences were analyzed using Nextclade Web (https://clades.nextstrain.org) for further quality control and clade assignment.

RNAseq.

RNAseq was performed on lung post-mortem biopsy samples from 24 individuals which included 8 that were COVID culture-positive and 16 that were culture-negative.

Total RNA was extracted from lung biopsy samples using the RNeasy mini plus kit (Qiagen). Ribosomal depletion was performed, and libraries were prepared using the MGIEasy RNA Library Prep Set (Cat. No.: 1000006383, 1000006384, MGI, Shenzhen, China) as per

manufacturer's instructions. Sequencing was performed at the South African Medical Research

Council Genomics Centre using DNA nanoball-based technology on the DNBSEQ-G400

(BGI, Shenzhen China) instrument generating 100 bp unstranded paired-end reads. The

FastOC program [version 0.11.9; (1)], was used to assess read quality. The Spliced Transcripts

Alignment to a Reference (STAR) software [version STAR_2.7.7a; (2)] was used to map reads

consecutively to the Ensembl (3) human genome primary assembly (version GRCh38.109) and

the SARS CoV-2 reference (ASM985889v3) with the quantMode and GeneCounts option

selected to generate raw genewise read counts for each sample. A number of samples failed to

pass QC due to a low number of mapped reads (< 2 million). A total of six culture-positive and

five culture-negative samples were used in subsequent analysis.

The differential expression (DE) analysis was performed with the edgeR [version 3.38.4; (4)]

Bioconductor (5) package. Briefly, raw counts were filtered to remove genes with low

expression, normalized, and negative binomial generalized linear models were fitted. The

likelihood ratio test was used to identify DE genes when comparing culture-positive to culture-

negative samples.

A gene set enrichment analysis (GSEA) for Gene Ontology (Biological Process) was

performed on the DE results ranked by fold change using the gseGO function, from the R

clusterProfiler (ver: .4.4.4, PMID: 34557778) package.




Figure S1. *In vitro* **culture of SARS-CoV-2.** (**A**) Light microscope images showing SARS-CoV-2 viral-induced cytopathic effects (red arrow). (**B**) Confocal microscopy showing SARS-CoV-2 (red) infecting the cell line. DAPI (blue) was used as the nuclear stain. (**C**) The limit of detection (LOD) for the PCR assay to detect replicating competent SARS-CoV-2. SARS-CoV-2 viral stock was diluted in 10-fold dilutions from 1×10⁵ to 1 copy/ml and co-cultured with confluent H1299 ACE2 cells in a 24-well plate for 9 days. Aliquots were analysed by PCR for viral load on days 1, 3, 6 and 9. The relative viral load (copies/ml) are shown. The dotted line represents the LOD for viral load (1×10¹ copies/ml).

Supplementary results.

Table S1. Demographic and clinical characteristics of the decedents.

| | All | Lung biopsy | Lung biopsy | Univariat | Multivariate |
|---------------------|------------|------------------|---------------|-----------|----------------------|
| | Patients | culture-positive | culture- | e | [#] p-value |
| | n=42 | n=16 | negative | #p-value | |
| | | | n=26 | | |
| Gender | | | | 0.758 | 0.758 |
| Male | 47.6% | 43.8% (7/16) | 50% (13/26) | | |
| | (20/42) | | | | |
| Female | 52.3% | 56.3% (9/16) | 50% (13/26) | | |
| | (22/42) | | | | |
| Median age in years | 53 (41-62) | 58.5 (45.5-64) | 49.5 (41-60) | 0.2 | - |
| (range) | | | | | |
| Admission to ICU | | | | | |
| §BMI status | | | | | |
| Underweight | 37.5% | 25% (2/8) | 43.8% (7/16) | 0.657 | |
| | (9/24) | | | | |
| Normal | 25% (6/24) | 25% (2/8) | 25% (4/16) | - | |
| Overweight | 25% (6/24) | 25% (2/8) | 18.8% (3/16) | - | |
| Obese | 4% (1/24) | 12.5% (1/8) | 5% (1/16) | - | |
| Morbidly obese | 12.5% | 12.5% (1/8) | 6% (1/16) | - | |
| | (3/24) | | | | |
| Unknown | 83.3% | 62.5% (5/8) | 93.8% (15/16) | 0.091 | |
| | (20/24) | | | | |
| *Co- morbidities | | | | | |
| COPD/Chronic | 16.6% | 12.5% (1/8) | 18.8% (3/16) | - | 0.536 |

| bronchitis | (4/24) | able under a CC-B1-ND 4 | | | |
|----------------------|-----------|-------------------------|---------------|-------|-------|
| Obesity | 41.7% | 50% (4/8) | 37.5% (6/16) | 0.415 | - |
| | (10/24) | | | | |
| Diabetes | 16.6% | 25% (2/8) | 12.5% (2/16) | 0.589 | 0.673 |
| | (4/24) | | | | |
| Cancer | 33.3% | 12.5% (1/8) | 43.8% (7/16) | 0.189 | 0.578 |
| | (8/24) | | | | |
| Hypertension | 8.3% | 12.5% (1/8) | 6% (1/16) | - | 0.189 |
| | (2/24) | | | | |
| | | | | | |
| WOther | 4% (1/24) | 0% (0/8) | 6% (1/16) | - | - |
| | | | | | |
| HIV-positive | 14.3% | 18.8% (3/16) | 11.5% (3/26) | 0.658 | 0.392 |
| | (6/42) | | | | |
| *Vaccination status | | | | | |
| Yes | 12.5% | 0% (0/8) | 18.8% (3/16) | 0.526 | |
| | (3/24) | | | | |
| No | 87.5% | 100% (8/8) | 81.2% (13/16) | 0.526 | |
| | (21/24) | | | | |
| Smoker | 7.1% | 12.5% (2/16) | 3.8% (1/26) | 0.547 | |
| | (3/42) | | | | |
| SARS-CoV-2 variant | | | | | |
| detected in the Beta | | | | | |
| group by whole | | | | | |
| genome sequencing | | | | | |
| Beta B1.1.448 | 12.5% | 12.5% (1/8) | - | - | |
| | (1/8) | | | | |

| Unknown | 83.3% | 62.5% (5/8) | 1000/ /10/10 | | |
|-----------------------|------------|--------------|---------------|-------|-------|
| Chriown | 03.370 | 02.5/0 (5/0) | 100% (10/10) | _ | |
| | | , , | 100% (10/10) | _ | |
| | (15/18) | | | | |
| SARS-CoV-2 variant | | | | | |
| detected in the Delta | | | | | |
| group by whole | | | | | |
| genome sequencing | | | | | |
| Alpha V1 | 4% (1/24) | 12.5% (1/8) | 0% (0/16) | 0.149 | |
| Beta V2 | 4% (1/24) | 0% (0/8) | 6.3% (1/16) | 0.470 | |
| Delta 21J | 29.2% | 25% (2/8) | 31.3% (5/16) | 0.751 | |
| | (7/24) | | | | |
| Unknown | 62.5% | 50% (4/8) | 68.8% (11/16) | 0.371 | |
| | (15/24) | | | | |
| Secondary bacterial | | | | | |
| infection present | | | | | |
| (Biofire multiplex | | | | | |
| PCR) | | | | | |
| Yes | 40.5% | 50% (8/16) | 34.6% (9/26) | 0.518 | 0.518 |
| | (17/42) | | | | |
| No | 57.1% | 50% (8/16) | 61.5% (16/26) | 0.518 | |
| | (24/42) | | | | |
| Unknown | 2.4% | 0% (0/16) | 3.8% (1/26) | - | |
| | (1/42) | | | | |
| Bacterial | 11% (4/38) | 21% (3/14) | 4% (1/24) | 0.132 | 0.443 |
| bronchopneumonia | | | | | |
| (microbiologically | | | | | |
| and | | | | | |

| histopathologically | | lable under a CC-bY-ND 4 | | | |
|-----------------------|--------------|--------------------------|-----------------|-------|-------|
| confirmed) | | | | | |
| Steroid usage | | | | | |
| Yes | 79.5 % | 62.5% (10/16) | 88.5% (23/26) | 0.063 | 0.063 |
| | (33/42) | | | | |
| No | 21.4% | 37.5% (6/16) | 11.5% (3/26) | 0.063 | |
| | (9/42) | | | | |
| Median days of | 8 days (4.5- | 4.5 days (2.5- | 8 days (4.5-12) | 0.015 | |
| steroid usage (IQR) | 12) | 6.5) | n=16 | | |
| | n=24 | n=8 | | | |
| COVID-19 status at | | | | | |
| admission as assessed | | | | | |
| by nasopharyngeal | | | | | |
| swab PCR | | | | | |
| PCR positive | 90.5% | 93.8% (15/16) | 88.5% (23/26) | - | - |
| | (38/42) | | | | |
| COVID-19 antigen | 7.1% | 6.3% (1/16) | 11.5% (3/26) | - | |
| positive (no PCR | (3/42) | | | | |
| result) | | | | | |
| Unknown | 2.4% | 0% (0/16) | 3.8% (1/26) | - | |
| | (1/42) | | | | |
| Median Ct (IQR) | 26.1 (21.6- | 26.3 (20.9-28.3) | 25.6 (23.4- | 0.429 | |
| | 28.3) | n=11 | 29.7) | | |
| | n=27 | | n=16 | | |
| Ct value unknown | n=11 | n=4 | n=7 | | |
| COVID-19 status at | | | | | |
| time of MITS as | | | | | |

| assessed by | it is made avai | lable under a CC-BY-ND 2 | r.o memational license | | |
|----------------------|--------------------------|--------------------------|------------------------|-------|-------|
| nasopharyngeal swab | | | | | |
| | | | | | |
| PCR | | | | | |
| PCR positive | 85.7% | 100% (16/16) | 76.9% (20/26) | 0.067 | 0.003 |
| | (36/42) | | | | |
| PCR negative | 14.3% | 0% (0/16) | 23.1% (6/26) | 0.067 | |
| | (6/42) | | | | |
| Median Ct (IQR) | 23.5 (20.5- | 23.5 (17.7-25.6) | 26.2 (21.4- | 0.166 | |
| | 29.9) | n=15 | 30.1) | | |
| | n=33 | | n=18 | | |
| Ct value unknown | n=9 | n=1 | n=8 | | |
| Median time from | 17 (4-58) | 15 (5-27) | 18 (4-58) | 0.112 | 0.78 |
| onset of symptoms to | n=42 | n=16 | n=26 | | |
| death (range) | | | | | |
| Median days from | 5 days (1- | 3 days (1-17) | 8 days (0-48) | 0.061 | 0.043 |
| admission to ICU to | 48) | n=16 | n=26 | | |
| death (range) | n=42 | | | | |
| | | | | | |
| Median days from | 11 days (1- | 7 days (1-17) | 13 days (5-24) | 0.053 | 0.046 |
| administration of | 24) | n=7 | n=16 | | |
| high flow nasal | n=23 ^{D} | | | | |
| oxygen to death | | | | | |
| (range) | | | | | |
| | | | | | |

^{*}p-values are for comparison between lung culture-positive and negative.

[§]BMI status was only recorded for the Delta group.

*Co-morbidities were only recorded for the Delta group. No patients had asthma, current TB, other chronic lung disease, cardiovascular disease, CVA/stroke, malnutrition, organ failure/disease, anaemia, epilepsy, malignancy, on prior steroids or immunosuppressive therapy.

^gCt value at day of MITS sampling missing for 9 patients.

^a Vaccination status was only recorded for the Delta group.

WPatients with dyslipidemia, ex-smoker, previous lateral medullary syndrome, previous alcohol use, and history of ischemic heart disease.

[&]quot;Either the viral load was too low, or the sample was not available."

^D Only recorded for the Delta group.






Figure S2. In vitro viral culture of lung biopsies from MV decedents. Description of a new SARS-CoV-2 human biophenotype that has ongoing viral replication in lung for up to 27 days post symptom onset. The lung cancer cell line, H1299 ACE2, was used to culture SARS-CoV-2. The lung biopsy samples were removed and placed in the well containing the cellular monolayer. The inoculated cultures were grown in a humidified 37°C incubator and viral replication were monitored on days 1, 3, 6 and 9 by PCR. DSOTD=days

symptom onset to death.




Figure S3. Previously ventilated decedents had active replicating virus in the URT for up to 27 days post symptom onset to death. (A) The lung cancer cell line, H1299 ACE2, was used to culture SARS-CoV-2. The nasopharyngeal swabs in universal transport medium were initially filtered through a 0.22μm filter prior to inoculation. The inoculated cultures were grown in a humidified 37°C incubator with 5% CO₂ and cytopathic effect (CPE) and viral replication were monitored on days 1, 3, 6 and 9 by PCR. The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups are shown. The dotted lines represent the median days from symptom onset to death for the lung culture-positive (13 days) and lung culture-negative (18 days) decedents. The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups are shown for the Beta (B) and Delta (C) cohorts. The median days from symptom onset to death for the culture-positive (7 days for the Beta cohort and 16.5 days for the Delta cohort) and culture-negative (10.5 days for the Beta cohort and 23.5 days for the Delta cohort) participants are shown.




Figure S4. Electron micrographs of key clinical features of lung abnormalities associated with acute COVID-19 disease.

The size of the representative scale bars are shown.

Table S2. Histopathological data of the combined study cohort.

| Histology Tissue | All patients | culture- | culture- | p-value |
|--------------------------------|--------------|----------|------------|---------|
| | n=33* | positive | negative | |
| | | patients | patients | |
| | | n=13 | n=20 | |
| LUNG | | | | |
| Alveolar hyaline membranes | 24/33 | 8/13 | 16/20 | 0.425 |
| | (73%) | (61.5%) | (80%) | |
| Interstitial oedema | 7/19 (37%) | 3/7 | 4/12 (33%) | - |
| | | (43%) | | |
| Collapsed alveoli | 9/33 (27%) | 3/13 | 6/20 (30%) | - |
| | | (23%) | | |
| Pneumocyte denudation/necrosis | 24/33 | 9/13 | 15/20 | - |
| | (73%) | (69.2%) | (75%) | |
| Endothelial necrosis | 5/19 (26%) | 3/7 | 2/12 (17%) | 0.305 |
| | | (43%) | | |
| Vascular neutrophil aggregate | 6/19 (32%) | 3/7 | 3/12 (25%) | 0.617 |
| | | (43%) | | |
| Micro-thromboembolic | 11/33 | 5/13 | 6/20 (30%) | 0.714 |
| | (33%) | (38.5%) | | |
| Pulmonary haemorrhage | 14/33 | 3/13 | 11/20 | 0.087 |
| | (42%) | (23%) | (55%) | |
| Pulmonary endothelialitis | 5/19 (26%) | 2/7 | 3/12 (25%) | - |
| | | (29%) | | |
| Organising hyaline membranes | 15/19 | 6/7 | 9/12 (75%) | - |
| | (79%) | (86%) | | |

| Fibroblasts/myofibroblasts | 16/19 | 6/7 | 10/12 | - |
|-----------------------------------|------------|----------|------------|-------|
| proliferation | (84%) | (86%) | (83%) | |
| Lymphocytic infiltration | 26/33 | 9/13 | 17/20 | 0.393 |
| | (79%) | (69.2%) | (85%) | |
| Plasma cell infiltration | 4/19 (21%) | 1/7 | 3/12 (25%) | - |
| | | (14%) | | |
| Type II pneumocytes proliferation | 30/33 | 10/13 | 20/20 | 0.052 |
| | (91%) | (77%) | (100%) | |
| Atypical pneumocytes | 18/19 | 7/7 | 11/12 | - |
| | (95%) | (100%) | (92%) | |
| Atypical pneumocyte cytomegaly | 25/33 | 9/13 | 16/20 | 0.681 |
| | (76%) | (69%) | (80%) | |
| Atypical pneumocyte nucleomegaly | 21/33 | 7/13 | 14/20 | 0.465 |
| | (64%) | (54%) | (70%) | |
| Atypical pneumocyte | 19/33 | 6/13 | 13/20 | 0.472 |
| multinucleation | (58%) | (46%) | (65%) | |
| Atypical pneumocyte syncytia | 5/33 (15%) | 3/13 | 2/20 (10%) | 0.360 |
| | | (23%) | | |
| Foamy pneumocytes | 19/19 | 7/7 | 12/12 | - |
| | (100%) | (100%) | (100%) | |
| Arterial/arteriole thrombosis | 0/19 (0%) | 0/7 (0%) | 0/12 (0%) | - |
| Diffuse collagenous fibrosis | 0/19 (0%) | 0/7 (0%) | 0/12 (0%) | - |
| Subpleural/interstitial fibrosis | 7/19 (37%) | 2/7 | 5/12 (42%) | 0.657 |
| | | (29%) | | |
| Honeycomb | 5/33 (15%) | 2/13 | 4/20 (20%) | - |
| | | (15.4%) | | |
| Traction bronchiectasis | 0/19 (0%) | 0/7 (0%) | 0/12 (0%) | - |

| Squamous met | 1/19 (5%) | 1/7 (14%) | 0/12 (0%) | 0.368 |
|-----------------------------------|------------|-----------|-------------|-------|
| Intimal fibrosis | 0/19 (0%) | 0/7 (0%) | 0/12 (0%) | - |
| Medial hypertrophy | 0/19 (0%) | 0/7 (0%) | 0/12 (0%) | - |
| Organising pneumonia | 10/33 | 4/13 | 6/20 (30%) | - |
| | (30%) | (31%) | | |
| Bronchopneumonia (neutrophilic | 10/33 | 5/13 | 5/20 (25%) | 0.461 |
| infiltrate into the alveoli) | (30%) | (38.5%) | | |
| Intranuclear inclusions | 0/33 (0%) | 0/13 | 0/20 (0%) | - |
| | | (0%) | | |
| Intracytoplasmic inclusions | 0/33 (0%) | 0/13 | 0/20 (0%) | - |
| | | (0%) | | |
| Megakaryocytes | 22/33 | 8/13 | 14/20 | 0.714 |
| | (68%) | (71%) | (70%) | |
| Lung haemophagocytosis (increased | 17/33 | 3/13 | 14/20 | 0.013 |
| alveolar macrophages) | (52%) | (23%) | (70%) | |
| Lung siderophages | 6/33 (18%) | 2/13 | 4/20 (20%) | - |
| | | (15.4%) | | |
| Necrotising granulomas | 1/33 (3%) | 1/13 | 0/20 (7.7%) | 0.625 |
| | | (0%) | | |
| Non-necrotising granulomas | 0/33 (0%) | 0/13(0%) | 0/20 (0%) | - |
| HEART | | | | |
| Isolated myocyte necrosis | 6/33 (18%) | 1/13 | 5/20 (25%) | 0.364 |
| | | (14%) | | |
| Cardiac ischaemia | 8/17 (47%) | 3/7 | 5/10 (50%) | - |
| | | (43%) | | |

| Card capillary neutrophil 0/17 (0%) 0/7 (0%) 0/10 (0%) - margination RBC fragment 0/17 (0%) 0/7 (0%) 0/10 (0%) - Lipofuscin 17/17 7/7 10/10 - (100%) (100%) (100%) Enlarged nuclei 23/33 10/13 13/20 0.467 (70%) (77%) (65%) Cardiac interstitial fibrosis 20/33 4/13 16/20 0.001 (61%) (31%) (80%) Heart endothelialitis 1/33 (3%) 0/13 1/20 (10%) - (0%) Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - (0%) Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 (7.7%) Cardiac histiocytes 2/33 (6%) 1/13 1/20 (5%) - |
|---|
| margination 0/17 (0%) 0/7 (0%) 0/10 (0%) - RBC fragment 0/17 (0%) 0/7 (0%) 0/10 (0%) - Lipofuscin 17/17 7/7 10/10 - (100%) (100%) (100%) (100%) 0.467 Enlarged nuclei 23/33 10/13 13/20 0.467 (70%) (77%) (65%) 0.001 (61%) (31%) (80%) 0.001 Heart endothelialitis 1/33 (3%) 0/13 1/20 (10%) - Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| RBC fragment 0/17 (0%) 0/7 (0%) 0/10 (0%) - Lipofuscin 17/17 7/7 10/10 - (100%) (100%) (100%) 0.467 (23/33 10/13 13/20 0.467 (70%) (77%) (65%) Cardiac interstitial fibrosis 20/33 4/13 16/20 0.001 (61%) (31%) (80%) Heart endothelialitis 1/33 (3%) 0/13 1/20 (10%) - (0%) (0%) Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| Lipofuscin 17/17 7/7 10/10 - (100%) (100%) Enlarged nuclei 23/33 10/13 13/20 0.467 (70%) (77%) (65%) Cardiac interstitial fibrosis 20/33 4/13 16/20 0.001 (61%) (31%) (80%) Heart endothelialitis 1/33 (3%) 0/13 1/20 (10%) - (0%) Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - (0%) Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| Cardiac interstitial fibrosis 20/33 4/13 16/20 0.467 |
| Enlarged nuclei 23/33 10/13 13/20 0.467 (70%) (77%) (65%) Cardiac interstitial fibrosis 20/33 4/13 16/20 0.001 (61%) (31%) (80%) Heart endothelialitis 1/33 (3%) 0/13 1/20 (10%) - (0%) Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - (0%) Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| (70%) (77%) (65%) Cardiac interstitial fibrosis 20/33 4/13 16/20 0.001 (61%) (31%) (80%) Heart endothelialitis 1/33 (3%) 0/13 1/20 (10%) - (0%) (0%) Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - (0%) Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| Cardiac interstitial fibrosis 20/33 |
| (61%) (31%) (80%) Heart endothelialitis 1/33 (3%) 0/13 1/20 (10%) - (0%) (0%) 0/20 (0%) - Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - (0%) (0%) 1/13 4/20 (20%) 0.625 (7.7%) (7.7%) 0.625 |
| Heart endothelialitis 1/33 (3%) 0/13 (0%) Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - (0%) Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - (0%) Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| Cardiac neutrophils 0/33 (0%) 0/13 0/20 (0%) - (0%) Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| (0%) Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 |
| Cardiac lymphocytes 5/33 (15%) 1/13 4/20 (20%) 0.625 (7.7%) |
| (7.7%) |
| |
| Cardiac histiocytes 2/33 (6%) 1/13 1/20 (5%) - |
| |
| (7.7%) |
| Cardiac eosinophils 1/33 (3%) 0/13 1/20 (5%) - |
| (0%) |
| Cardiac interstitial oedema 4/33 (12%) 0/13 4/20 (20%) 0.136 |
| (0%) |
| LIVER |
| Increase Kupffer 16/17 7/7 9/10 (90%) - |
| (94%) (100%) |

| It is made available ur | | | | 0.00 |
|---------------------------|------------|----------|------------|-------|
| Foamy Kupffer | 4/17 (24%) | 1/7 | 3/10 (30%) | 0.603 |
| | | (14%) | 7/20 (27) | |
| Liver haemophagocytosis | 9/33 (27%) | 4/13 | 5/20 (25%) | - |
| | | (31%) | | |
| Liver siderophages | 1/33 (3%) | 0/13 | 1/20 (5%) | - |
| | | (0%) | | |
| Liver necrosis | 7/17 (41%) | 3/7 | 4/10 (40%) | - |
| | | (43%) | | |
| Spotty necrosis zone 1 | 0/17 (0%) | 0/7 (0%) | 0/10 (0%) | - |
| Spotty necrosis zone 2 | 2/16 (13%) | 1/6 | 1/10 (10%) | - |
| | | (17%) | | |
| Spotty necrosis zone 3 | 2/17 (12%) | 1/7 | 1/10 (10%) | - |
| | | (14%) | | |
| Confluent necrosis zone 1 | 0/17 (0%) | 0/7 (0%) | 0/10 (0%) | - |
| Confluent necrosis zone 2 | 1/17 (6%) | 0/7 (0%) | 1/10 (10%) | - |
| Confluent necrosis zone 3 | 4/17 (24%) | 1/7 | 3/10 (30%) | 0.603 |
| | | (14%) | | |
| Micro steatosis | 14/17 | 6/7 | 8/10 (80%) | - |
| | (82%) | (86%) | | |
| Macro steatosis | 13/17 | 6/7 | 7/10 (70%) | - |
| | (76%) | (86%) | | |
| Cholestasis | 8/33 (24%) | 3/13 | 5/20 (25%) | - |
| | | (23%) | | |
| Liver inflammation | 9/17 (53%) | 3/7 | 6/10 (60%) | 0.637 |
| | | (43%) | | |
| Liver regeneration | 16/17 | 7/7 | 9/10 (90%) | - |
| | (94%) | (100%) | | |
| | | | | |

| Liver congestion | 9/33 (%) | 8/13 | 11/20 | - |
|---------------------------------|------------|----------|------------|-------|
| | | (61.5%) | (55%) | |
| Liver viral inclusions | 0/17 (0%) | 0/7 (0%) | 0/10 (0%) | - |
| Liver fibrosis F1 | 2/17 (12%) | 1/7 | 1/10 (10%) | - |
| | | (14%) | | |
| Liver fibrosis F2 | 0/17 (0%) | 0/7 (0%) | 0/10 (0%) | - |
| Liver fibrosis F3 | 1/17 (6%) | 0/7 (0%) | 1/10 (10%) | - |
| Liver fibrosis F4 | 1/17 (6%) | 0/7 (0%) | 1/10 (10%) | - |
| Primary sclerosing cholangitis | 0/17 (0%) | 0/7 (0%) | 0/10 (0%) | - |
| Primary biliary cholangitis | 0/17 (0%) | 0/7 (0%) | 0/10 (0%) | - |
| Extramedullary haematopoiesis | 0/17 (0%) | 0/7 (0%) | 0/10 (0%) | - |
| (EMH) | | | | |
| KIDNEY | | | | |
| Glom capillary dilatation | 10/11 | 5/5 | 5/6 (83%) | - |
| | (91%) | (100%) | | |
| Glom thrombus | 4/11 (36%) | 0/5 (0%) | 4/6 (67%) | 0.061 |
| Glom sclerosis | 3/11 (27%) | 0/5 (0%) | 3/6 (50%) | 0.182 |
| Increase mesangium | 7/11 (64%) | 3/5 | 4/6 (67%) | - |
| | | (60%) | | |
| Membrane thickening | 0/11 (0%) | 0/5 (0%) | 0/6 (0%) | - |
| Acute kidney injury | 4/11 (36%) | 0/5 (0%) | 4/6 (67%) | 0.061 |
| Tubular casts | 6/11 (55%) | 2/5 | 4/6 (67%) | 0.242 |
| | | (40%) | | |
| Isometric vacuole | 0/11 (0%) | 0/5 (0%) | 0/6 (0%) | - |
| Kidney interstitial lymphocytes | 1/11 (9%) | 1/5 | 0/6 (0%) | - |
| | | (20%) | | |

| Kidney interstitial plasma | 1/11 (9%) | 1/5 | 0/6 (0%) | - |
|------------------------------|----------------------|----------|-------------------------|-------|
| | | (20%) | | |
| Kidney interstitial fibrosis | 2/11 (18%) | 0/5 (0%) | 2/6 (33%) | 0.455 |
| Kidney interstitial haem | 0/11 (0%) | 0/5 (0%) | 0/6 (0%) | - |
| Kidney arteriosclerosis | 4/11 (36%) | 1/5 | 3/6 (50%) | 0.546 |
| | | (20%) | | |
| ADIPOSE | | | | |
| Fat necrosis | 10/21 | 6/8 | 4/13 (31%) | 0.082 |
| | (48%) | (75%) | | |
| | | | | |
| Fat fibrin | 0/21 (0%) | 0/8 (0%) | 0/13 (0%) | - |
| Fat fibrin Fat unremarked | 0/21 (0%) 11/21 (52) | 0/8 (0%) | 0/13 (0%) 9/13 (69%) | 0.082 |

^{*}Histopathology was not performed on all the biopsy samples.

Table S3. Electron microscopy data of the Delta cohort.

| Histology Tissue | All patients | culture- | culture- | p-value |
|-------------------------------|--------------|----------|------------|---------|
| | n=17* | positive | negative | |
| | | patients | patients | |
| | | n=7 | n=10 | |
| LUNG | | | | |
| Pneumocyte vacuolation | 13/17 | 6/7 | 7/10 (70%) | 0.603 |
| | (76%) | (86%) | | |
| Endothelial vacuolation | 3/17 (18%) | 2/7 | 1/10 (10%) | 0.537 |
| | | (29%) | | |
| Endothelial swelling | 13/17 | 6/7 | 7/10 (70%) | 0.603 |
| | (76%) | (86%) | | |
| Activated capillary monocytes | 1/17 (6%) | 0/7 (0%) | 1/10 (10%) | - |
| Pneumocyte detachment | 15/17 | 7/7 | 8/10 (80%) | 0.485 |
| | (88%) | (100%) | | |
| Collagen deposits | 11/16 | 5/6 | 6/10 (60%) | 0.588 |
| | (69%) | (83%) | | |
| HEART | | | | |
| Mitochondrial hypoxic changes | 12/12 | 6/6 | 6/6 (100%) | - |
| | (100%) | (100%) | | |
| Myocyte atrophy and wrinkling | 11/11 | 6/6 | 5/5 (100%) | - |
| | (100%) | (100%) | | |
| Lipofuscin | 7/11 (64%) | 5/6 | 2/5 (40%) | 0.242 |
| | | (83%) | | |
| Swollen endothelial | 10/11 | 6/6 | 4/5 (80%) | - |
| | (91%) | (100%) | | |

| Fragmented red blood cells | 4/11 (36%) | 0 International lic | 0/5 (0%) | 0.061 |
|-----------------------------------|------------|---------------------|------------|-------|
| | | (57%) | | |
| Myofibrillar disruption | 5/11 (45%) | 4/6 | 1/5 (20%) | 0.242 |
| | | (57%) | | |
| LIVER | | | | |
| Swollen/hypoxic mitochondria | 15/15 | 6/6 | 9/9 (100%) | - |
| | (100%) | (100%) | | |
| Increased Kupffer | 2/15 (13%) | 1/6 | 1/9 (11%) | - |
| | | (17%) | | |
| Steatosis | 7/15 (47%) | 2/6 | 5/9 (56%) | 0.398 |
| | | (33%) | | |
| Haemophagocytosis | 10/15 | 4/6 | 6/9 (67%) | - |
| | (67%) | (57%) | | |
| Detached of endothelial cells | 7/15 (47%) | 3/6 | 4/9 (44%) | - |
| | | (50%) | | |
| Lipidized stellate cells | 7/15 (47%) | 3/6 | 4/9 (44%) | - |
| | | (50%) | | |
| EM liver cholestasis | 2/14 (14%) | 1/6 | 1/8 (13%) | - |
| | | (17%) | | |
| ADIPOSE | | | | |
| Normal mitochondria | 3/14 (21%) | 0/6 (0%) | 3/8 (38%) | 0.209 |
| Slightly enlarged mitochondria | 5/14 (36%) | 4/6 | 1/8 (13%) | 0.091 |
| | | (57%) | | |
| Enlarged mitochondria | 6/14 (43%) | 2/6 | 4/8 (50%) | 0.627 |
| | | (33%) | | |
| Swollen endothelial cells present | 9/11 (82%) | 4/4 | 5/7 (71%) | 0.491 |
| | | (100%) | | |

^{*}EM was only performed on biopsy samples in the Delta cohort.




Figure S5. Gene expression profile in the culture-negative and culture-positive groups cluster into distinct groups. PCA plot (A) and heatmap (B) showing that distinct genes are differentially regulated in the culture-positive and culture-negative groups.

Table S4. Bacteria and antibiotic resistance profile detected from the lung biopsies of the decedents using multiplex PCR (Biofire).

| Patient | Seconda | Numb | er Bacterial species present | Bacterial | Antibiotic resistance |
|---------|-----------|---------|------------------------------|-------------------|-----------------------|
| ID | ry | of | | load | |
| | bacterial | differe | nt | (copies/ml) | |
| | infection | bacter | ia | | |
| | present | specie | es | | |
| | | preser | nt | | |
| | | | | | |
| UCT | Yes | 2 | Staphylococcus aureus | 1×10 ⁶ | None detected |
| 001 | | | Streptococcus pneumoniae | 1x10 ⁴ | |
| UCT | No | _ | - | - | - |
| | NO | _ | - | _ | - |
| 002 | | | | | |
| UCT | No | - | - | - | - |
| 003 | | | | | |
| UCT | No | - | - | - | - |
| 004 | | | | | |
| UCT | No | - | - | - | - |
| 005 | | | | | |
| UCT | No | - | - | - | - |
| 007 | | | | | |
| UCT | No | | _ | | |
| | NO | _ | - | - | - |
| 008 | | | | | |
| UCT | Yes | 1 | Staphylococcus aureus | $1x10^5$ | None detected |
| 009 | | | | | |
| UCT | Yes | 2 | Staphylococcus aureus | 1x10 ⁵ | None detected |
| 010 | | | Streptococcus agalactiae | 1x10 ⁴ | |

| UCT | Yes | 2 | Haemophilus influenzae | 1×10^6 | None detected |
|-----|--------|---|-------------------------------|-------------------|-------------------|
| 012 | | | Staphylococcus aureus | 1x10 ⁶ | |
| UCT | No | - | - | - | - |
| 013 | | | | | |
| UCT | Yes | 1 | Acinetobacter calcoaceticus - | 1x10 ⁵ | Carbapenem (NDM) |
| 014 | | | baumannii complex | | |
| UCT | No | - | - | - | - |
| 016 | | | | | |
| UCT | No | - | - | - | - |
| 017 | | | | | |
| UCT | Yes | 2 | Acinetobacter calcoaceticus - | $1x10^{6}$ | β-lactam (CTX-M) |
| 018 | | | baumannii complex | | Carbapenenm (NDM) |
| | | | | 1x10 ⁶ | |
| | | | Protous ann | | |
| | | | Proteus spp. | | |
| UCT | No | - | | | |
| 020 | | | | | |
| UCT | No | - | - | - | - |
| 021 | | | | | |
| UCT | No | - | - | - | - |
| 022 | | | | | |
| UCT | Yes | 1 | Staphylococcus aureus | 1x10 ⁵ | None detected |
| 023 | | | | | |
| UCT | Unknow | - | - | - | - |
| 024 | n | | | | |
| UCT | No | - | - | - | - |
| 026 | | | | | |

| UCT | No | _ | It is made available under a CC-BY-ND 4.0 | - | - |
|------|-----|---|---|-------------------|--------------------------|
| 027 | | | | | |
| UCT | No | - | - | - | - |
| 028 | | | | | |
| WITS | Yes | 1 | Streptococcus agalactiae | $1x10^{6}$ | |
| 2305 | | | | | |
| WITS | No | - | - | - | - |
| 5033 | | | | | |
| WITS | Yes | 6 | Escherichia coli | $1x10^{7}$ | None detected |
| 5419 | | | Staphylococcus aureus | 1x10 ⁷ | |
| | | | Streptococcus agalactiae | 1x10 ⁶ | |
| | | | Klebsiella oxytoca | 1x10 ⁵ | |
| | | | Enterobacter cloacae complex | 1x10 ⁴ | |
| | | | Klebsiella pneumoniae group | 1x10 ⁴ | |
| WITS | Yes | 2 | Serratia marcescens | 1x10 ⁵ | β-lactam (CTX-M) |
| 5502 | | | Klebsiella pneumoniae group | $1x10^{4}$ | Carbapenem (OXA-48- |
| | | | | | like) |
| WITS | No | - | - | - | - |
| 5517 | | | | | |
| WITS | Yes | 3 | Escherichia coli | 1x10 ⁴ | β-lactam (CTX-M) |
| 5619 | | | Klebsiella pneumoniae | $1x10^{4}$ | Carbapenem (OXA-48-like) |
| | | | Serratia marcescens | 1x10 ⁴ | |
| WITS | Yes | 7 | Enterobacter cloacae complex | 1x10 ⁷ | β-lactam (CTX-M) |
| 5650 | | | Klebsiella oxytoca | 1x10 ⁷ | Carbapenem (NDN) |
| | | | Klebsiella pneumoniae group | 1x10 ⁷ | Carbapenem (OXA-48-like) |
| | | | Streptococcus pneumoniae | 1x10 ⁷ | |
| | | | Escherichia coli | 1x10 ⁶ | |

| | | | Acinetobacter calcoaceticus- | 1×10^4 | |
|-------|-----|---|------------------------------|-----------------|--------------------------|
| | | | Acthetobacter catcoaceticus- | 1X10 | |
| | | | baumannii complex | | |
| | | | • | | |
| WITS | No | - | - | - | - |
| 6182 | | | | | |
| 0102 | | | | | |
| WITS | No | - | - | - | - |
| | | | | | |
| 7659 | | | | | |
| WITS | Yes | 2 | Acinetobacter calcoaceticus- | $1x10^{6}$ | β-lactam (CTX-M) |
| | | | | | , |
| 8734 | | | baumannii complex | $1x10^4$ | Carbapenem (NDM) |
| | | | Klebsiella pneumoniae group | | Carbapenem (OXA-48-like) |
| | | | - | | - |
| WITS | Yes | 2 | Escherichia coli | $1x10^4$ | β lactam (CTX-M) |
| 9156 | | | Klebsiella pneumoniae | $1x10^{4}$ | |
| 7130 | | | Theosteria pheumoniae | INTO | |
| WITS | No | - | - | - | - |
| 12008 | | | | | |
| 12008 | | | | | |
| WITS | Yes | 2 | Klebsiella pneumoniae | $1x10^{7}$ | Carbapenem (OXA-48-like) |
| 10010 | | | | 1 101 | |
| 12010 | | | Pseudomonas aeruginosa | $1x10^4$ | |
| WITS | No | _ | - | - | - |
| | | | | | |
| 12011 | | | | | |
| WITS | Yes | 2 | Streptococcus pneumoniae | $1x10^{7}$ | None detected |
| | | | | | |
| 12019 | | | Streptococcus agalactiae | $1x10^4$ | |
| WITS | No | _ | - | _ | - |
| | | | | | |
| 12024 | | | | | |
| WITS | No | _ | - | _ | _ |
| | | | | | |
| 12068 | | | | | |
| WITS | Yes | 1 | Strantacoccus programoniae | $1x10^4$ | None detected |
| WILL | 168 | 1 | Streptococcus pneumoniae | 1A10 | rone detected |
| 12115 | | | | | |
| | | | | | |

Table S5. Whole genome sequencing results of the viral variants from the study cohort. Only 6 culturenegative and 6 culture-positive samples were available for sequencing because either the viral load was too low (Ct>30) or the sample was not available. It was therefore impossible to perform comparative analysis between the 2 groups because of the small sample number. Data was analysed and sequences aligned using Stanford Coronavirus Antiviral Resistance the University and Database (available https://covdb.stanford.edu/).

| Patient | Source of | Variant | Lineag | Sub- | Gene | Unique | Comments | Ref |
|-----------------|--------------|---------|--------|---------|----------|-----------|----------|-----|
| \mathbf{ID}^* | sample | | e | lineage | | mutations | | |
| | | | | | | (found in | | |
| | | | | | | <0.01% of | | |
| | | | | | | genomes) | | |
| | | | | | | | | |
| WITS | Lung culture | Beta | 20B | B.1.1 | - | None | | |
| 1210 | supernatant | | | | | | | |
| WITS | Lung culture | Beta | 20H | B.1.3.5 | - | None | | |
| 12068 | supernatant | | | 1 | | | | |
| WITS | Lung culture | Beta | 20H | B.1.351 | - | None | | |
| 12115 | supernatant | | | | | | | |
| UCT 001 | NPS | Alpha | 20I | B1.1.7 | - | None | | |
| UCT 004 | NPS | Beta | 20H | B1.351 | | | | |
| UCT 028 | NPS | Delta | 21J | AY6 | - | None | | |
| UCT 016 | NPS | Delta | 21J | AY91 | | | | |
| UCT 008 | NPS | Delta | 21J | AY32 | Papain- | C55C*W | | |
| | | | | | like | E113EAGV | | |
| | | | | | protease | E115ED | | |
| | | | | | (PLpro) | C118C*W | | |
| | | | | | | | | |
| | | | | | Helicase | P593DE | | |
| | | | | | (nsp13) | R594X | | |
| | | | | | mRNA | K433KN | | |
| | | | | | capping | P443PAST | | |

| | | n io mado | | | protein | K469KMRT | | |
|------------|-------|-----------|-----|---------|----------|-----------|-----------------|-----|
| | | | | | (nsp 14) | A471APST | | |
| | | | | | | | | |
| | | | | | Membra | S211R | | |
| | | | | | ne (M) | S212*DEHQ | | |
| | | | | | | Y | | |
| | | | | | | S213X | | |
| UCT 012 | NPS | Delta | 21J | AY32 | - | None | | |
| UCT 018 | NPS | Delta | 21J | B1.617. | Main | A191T | A191T is a | (6) |
| | | | | 2 | protease | | reported | |
| | | | | | (PLpro) | | resistance | |
| | | | | | | | mutation | |
| | | | | | | | against 3C- | |
| | | | | | | | like protease | |
| | | | | | | | inhibitor, i.e. | |
| | | | | | | | nirmatrelvir. | |
| | | | | | | | | |
| | | | | | RdRP | H650N | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | Spike | V16VFIL | | |
| | | | | | 1 | K77E | | |
| | | | | | | II, / L | | |
| | | | | | | | | |
| | | | | | Nucleoca | S255A | | |
| | | | | | psid | 5233A | | |
| UCT 022 | NPS | Delta | 21J | AY32 | | Saguanas | | |
| 001 022 | INL O | Deila | ∠1J | A 1 32 | - | Sequence | | |
| TIOTE 02.4 | NIDG | D. I. | 011 | 4 37.5 | 3.6 | missing | | |
| UCT 024 | NPS | Delta | 21J | AY6 | Main | N1454NIST | | |
| | | | | | protease | | | |
| | | | | | (PLpro) | | | |
| | | | | | | | | |

| | 1010111000 | | | | I | |
|--|------------|--|-----------|-----------|---|--|
| | | | Helicase | F587L | | |
| | | | | | | |
| | | | (nsp13) | | | |
| | | | | | | |
| | | | | T588TIR | | |
| | | | | | | |
| | | | mRNA | M72X | | |
| | | | _ | D 405DE | | |
| | | | capping | R485DE | | |
| | | | | **** | | |
| | | | protein | H486X | | |
| | | | (14) | 1140737 | | |
| | | | (nsp 14) | H487X | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | A | WO1D | | |
| | | | Accessor | K21R | | |
| | | | | D22D*EHOV | | |
| | | | y protein | D22D*EHQY | | |
| | | | (ODE2=) | 1 0 41 37 | | |
| | | | (ORF3a) | L94LV | | |
| | | | | | | |

Table S6. Transcriptomic analysis showing the DE genes in the culture-positive cohort relative to the culture-negative cohort. Genes in black text are human specific. Genes in red text are SARS-CoV-2 specific.

| ENZ_ID | Abbreviation | Gene name | logFC | logCPM | p value | FDR |
|-----------|--------------|--|--------|--------|----------|-------|
| 43740569 | ORF3a | ORF3a protein | 8.35 | -0.02 | 3,23E-07 | 0.005 |
| 43740575 | N | Nucleocapsid phosphoprotein | 5.5 | 2.14 | 1,09E-06 | 0.009 |
| 26585 | GREM1 | Gremlin 1, DAN family BMP antagonist | 3.1 | 5.43 | 2,85E-06 | 0.016 |
| 100271927 | RASA4B | RAS p21 protein activator 4B | -2.6 | 3.21 | 4,27E-06 | 0.018 |
| 27111 | SDCBP2 | Syndecan binding protein 2 | 1.67 | 3.38 | 8,53E-06 | 0.029 |
| 374 | AREG | Amphiregulin | 2.11 | 5 | 1,10E-05 | 0.031 |
| 771 | CA12 | Carbonic anhydrase 12 | 2.11 | 5.34 | 1,57E-05 | 0.034 |
| 5055 | SERPINB2 | Serpin family B member 2 | 4.43 | 2.5 | 1,81E-05 | 0.034 |
| 134285 | TMEM171 | Transmembrane protein 171 | 2.22 | -0.55 | 1,82E-05 | 0.034 |
| 338328 | GPIHBP1 | Glycosylphosphatidylinositol anchored high | -2.25 | 2.63 | 2,16E-05 | 0.035 |
| | | density lipoprotein binding protein 1 | | | | |
| 9982 | FGFBP1 | Fibroblast growth factor binding protein 1 | 2.65 | 2.07 | 2,44E-05 | 0.035 |
| 80320 | SP6 | Sp6 transcription factor | 1.67 | 1.8 | 2,53E-05 | 0.035 |
| 1847 | DUSP5 | Dual specificity phosphatase 5 | 1.95 | 5.27 | 2,87E-05 | 0.035 |
| 2537 | IFI6 | Interferon alpha inducible protein 6 | 2.22 | 6.62 | 2,95E-05 | 0.035 |
| 57126 | CD177 | CD177 molecule | 4.15 | 5.53 | 4,26E-05 | 0.047 |
| 4915 | NTRK2 | Neurotrophic receptor tyrosine kinase 2 | -2.453 | 4.7 | 5,63E-05 | 0.059 |
| 43740568 | S spike | Surface glycoprotein/spike glycoprotein | 5.32 | 2.06 | 6,84E-05 | 0.067 |
| 23105 | FSTL4 | Follistatin like 4 | -1.25 | 0.8 | 7,35E-05 | 0.068 |
| 6853 | SYN1 | Synapsin I | 1.95 | 2.28 | 8,13E-05 | 0.071 |
| 2827 | GPR3 | G protein-coupled receptor 3 | 2.07 | 0.53 | 9,07E-05 | 0.076 |

Table S7A. Pathways upregulated in the culture-positive cohort relative to the culture-negative cohort.

| | | Total | | | | |
|------------|----------------------------|------------|-------------|-------------|----------|----------|
| | | number of | | | | |
| | | genes | | | | |
| | | associated | | | | FDR |
| | | with the | Enrichment | | | |
| GO.ID | Pathway | pathway | score | NES | p value | |
| CO:0045097 | Innata immuna raspansa | 644 | 0.462041652 | 2 22077102 | 2 10E 26 | 1 05E 22 |
| GO:0045087 | Innate immune response | 044 | 0,462041652 | 2,23077102 | 3,19E-20 | 1,95E-22 |
| GO:0009617 | Response to bacterium | 502 | 0,436586937 | 2,063633461 | 1,46E-16 | 2,30E-13 |
| GO:0006954 | Inflammatory response | 666 | 0,397117204 | 1,910719799 | 1,84E-16 | 2,30E-13 |
| GO:0009615 | Response to virus | 337 | 0,482017466 | 2,192737214 | 4,76E-16 | 4,15E-13 |
| GO:0034097 | Response to cytokine | 784 | 0,378837973 | 1,853887449 | 4,57E-16 | 4,15E-13 |
| GO:0042742 | Defence response to | 187 | 0,57065003 | 2,468893487 | 2,87E-15 | 1,95E-12 |
| | bacterium | | | | | |
| GO:0097529 | Myeloid leukocyte | 197 | 0,560938069 | 2,429088511 | 7,89E-15 | 4,82E-12 |
| | migration | | | | | |
| GO:0071345 | Cellular response to | 700 | 0,379135852 | 1,832624826 | 1,29E-14 | 7,19E-12 |
| | cytokine stimulus | | | | | |
| GO:0060326 | Cell chemotaxis | 260 | 0,505415546 | 2,244480472 | 3,87E-14 | 1,69E-11 |
| GO:0030595 | Leukocyte chemotaxis | 199 | 0,543874673 | 2,355877738 | 7,37E-14 | 2,81E-11 |
| GO:1903047 | Mitotic cell cycle process | 679 | 0,37365134 | 1,802308085 | 9,44E-14 | 3,39E-11 |
| GO:0042330 | Taxis | 521 | 0,406071568 | 1,918906559 | 1,71E-13 | 5,80E-11 |
| GO:0050900 | Leukocyte migration | 334 | 0,461740475 | 2,094951262 | 1,90E-13 | 6,01E-11 |
| GO:0006935 | Chemotaxis | 519 | 0,406436107 | 1,934745764 | 1,97E-13 | 6,01E-11 |
| GO:0000280 | Nuclear division | 380 | 0,433965649 | 1,999760733 | 8,85E-13 | 2,35E-10 |

| GO:0019221 | Cytokine-mediated signalling pathway | 401 | 0,424428923 | 1,972848247 | 2,15E-12 | 5,46E-10 |
|------------|--|-----|-------------|-------------|----------|----------|
| GO:0007059 | Chromosome segregation | 305 | 0,457222273 | 2,071558403 | 2,72E-12 | 6,65E-10 |
| GO:0051301 | Cell division | 573 | 0,383696506 | 1,825281074 | 3,41E-12 | 7,87E-10 |
| GO:2000147 | Positive regulation of cell motility | 507 | 0,386349508 | 1,825320536 | 7,25E-12 | 1,53E-09 |
| GO:0002237 | Response to molecule of bacterial origin | 294 | 0,453670477 | 2,036098196 | 1,01E-11 | 2,05E-09 |

Table S7B. Other pathways of interest upregulated in the culture-positive cohort relative to the culturenegative cohort.

| | | Total number of genes associated with the | | | |
|------------|---|---|-------------|-------------|----------|
| GO.ID | Pathway | pathway | score | NES | FDR |
| GO:04657 | IL-17 signalling pathway | 81 | 0,635892 | 2.380892 | 1,53E-07 |
| GO:0002456 | T-cell-mediated immunity | 96 | 0,478752825 | 1,850434828 | 1,1E-03 |
| GO:0002825 | Regulation of T-helper 1 type immune response | 25 | 0,576145234 | 1,920646442 | 1,2E-3 |
| GO:0035710 | CD4-positive, alpha-beta T cell activation | 89 | 0,470392439 | 1,801972021 | 2,1E-03 |
| GO:0035743 | CD4-positive, alpha-beta T cell cytokine production | 15 | 0,774743052 | 2,055120611 | 3E-03 |
| GO:0002726 | Positive regulation of T cell cytokine production | 24 | 0,683190625 | 2,000311209 | 3,4E-03 |

| GO:0042110 | T cell activation | 448 | 0,294698908 | 1,379497641 | 3,5E-03 |
|------------|--|-----|-------------|-------------|---------|
| GO:2000514 | Regulation of CD4-positive, alpha-beta T cell activation | 56 | 0,519437379 | 1,853870959 | 5,8-03 |
| GO:0002711 | Positive regulation of T cell mediated immunity | 49 | 0,543959461 | 1,869533223 | 6,7E-3 |
| GO:0042088 | Th1 immune response | 41 | 0,576145234 | 1,920646442 | 6,7E-03 |
| GO:0002709 | Regulation of T-cell mediated immunity | 76 | 0,686930834 | 2,050809398 | 7,3E-03 |
| GO:0002369 | T-cell cytokine production | 34 | 0,610833263 | 1,94794025 | 9,1E-3 |
| GO:0002724 | Regulation of T cell cytokine production | 34 | 0,610833263 | 1,94794025 | 9,1E-03 |
| GO:0050868 | Negative regulation of T cell activation | 109 | 0,413862853 | 1,63976229 | 1,1E-02 |

Table S7C. Genes associated with regulatory pathways of were not up- or downregulated in the culturepositive cohort relative to the culture-negative cohort.

| ENZ ID | Gene | LogFC | p-value | FDR |
|--------|--------|--------------|-------------|-------------|
| 5133 | PD-1 | -0,580384672 | 0,352556526 | 0,875617669 |
| 64115 | VISTA | 0,195588418 | 0,601343382 | 0,941688131 |
| 84868 | TIM-3 | 0,243920799 | 0,568480759 | 0,936258857 |
| 1493 | CTLA-4 | 0,100226405 | 0,868488938 | 0,987403587 |
| 940 | CD28 | -0,515589978 | 0,192859859 | 0,773804865 |
| 945 | CD33 | -0,047967186 | 0,910411079 | 0,991670954 |
| 3559 | CD25 | -0,703108858 | 0,154569866 | 0,728675358 |
| 50943 | FOXP3 | -0,918764993 | 0,158003877 | 0,732211968 |




Figure S6. The culture-positive group expressed higher levels of genes associated with inflammatory, innate immunity and enhanced SARS-CoV-2 cellular entry pathways compared to the culture-negative cohort. Volcano plots showing the pathways (A) and individual genes (B and C) upregulated in the culture-positive versus the culture-negative cohort. Cyto = cytokine signalling, def. resp.virus = defence of respiratory virus, innate = innate immunology, inflame = inflammatory response, vir_ent=viral entry. The red line represents FDR<0.05 and the black dotted represents p<0.05.

Supplementary references.

- Andrews S. FastQC: A quality control tool for high throughput sequence data. Accessed on: 1st July 2022. Available at: https://www.bioinformatics.babraham.ac.uk/projects/fastqc. 2010.
- 2. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinform* 2013; **29**(1): 15-21.
- 3. Howe KL, Achuthan P, Allen J, et al. Ensembl 2021. *Nucleic Acids Res* 2021; **49**(D1): D884-D91.
- 4. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinform* 2010; **26**(1): 139-40.
- 5. Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods* 2015; **12**(2): 115-21.
- 6. Noske G D dSSE, de Godoy M O, Dolci I, Fernandes R S, Guido R V C, Sjö P, Oliva G, Godoy A S. Structural basis of nirmatrelvir and ensitrelvir resistance profiles against SARS-CoV-2 main protease naturally occurring polymorphisms. *J Biol Chem* 2023; **299**(3).